PCOS患者IVF治疗新策略
|
摘要
多囊卵巢综合征(Polycystic Ovary Syndrome, PCOS)是一种常见的内分泌紊乱综合征,在生育年龄的妇女人群中发病率约为5%,是引起育龄女性无排卵性不孕的主要原因[1]。约80%的PCOS患者可通过药物干预或腹腔镜下卵巢打孔术诱发排卵而自然受孕,但仍有20%的PCOS妇女需要在辅助生殖技术的帮助下才能妊娠。体外受精-胚胎移植技术(In vitro fertilization and embryo transfer, IVF-ET)是分别将卵子与精子从人体内取出后体外受精,发育成胚胎后再移植回母体子宫以帮助不孕夫妇建立妊娠的辅助生殖技术。该项技术的一个关键是控制性促排卵,用药物在可控制的范围内诱发多个卵泡的发育和成熟,得到高质量的卵子,形成多个可供筛选的胚胎进行移植,从而提高了每周期试管婴儿的成功率。
对于PCOS患者,临床上常规使用长效长方案进行促排卵。但是因PCOS患者往往伴有FSH分泌不足、LH分泌异常增高、高胰岛素血症、高雄激素血症等内分泌和代谢的异常,导致其IVF妊娠率低,促排后卵巢过度刺激综合征(Ovarian hyperstimulation syndrome, OHSS)等并发症发生率高[2]。对PCOS这一特殊人群,我们想找到一种更适合的促排卵方案,以获得更高的妊娠率、并减少促排卵并发症发生的风险。针对PCOS患者特殊的病理特征,我们前期发明了—种改良的超长方案。为了回答改良的超长方案是否可以提高PCOS患者的IVF妊娠率这一问题,在本论文的第一部分,我们分别通过回顾性和前瞻性的对照研究,比较了改良超长方案和长效长方案用于PCOS患者IVF治疗的各项临床指标和临床结局。
质量优良的胚胎在母体子宫内通过着床、分化,最终发育成一个成熟的胎儿。着床是建立成功妊娠的重要一步,而子宫内膜的容受性即子宫内膜接受胚胎的能力是着床的关键因素之一[3]。目前的观点认为,调节子宫内膜的容受性比较明确的指标有：子宫内膜的厚度、形态、血流,体内性激素水平,子宫内膜着床相关因子(如同源框基因相关蛋白产物和白细胞抑制因子)等。各个因素相互调节、作用,增加子宫内膜的容受性,使胚胎能够成功的植入。在人类着床窗口期,如子宫内膜厚度增加(>9mm)、内膜下血流指数上升、胞饮突出现、LIF、HOXA10基因等表达增加,则意味着良好的子宫内膜容受性[4、5]。因此,在本文的第二部分,为了探讨两种促排方案对子宫内膜容受性的影响,我们通过电镜检测了改良超长方案组和长效长方案组中PCOS患者着床窗口期胞饮突情况,用免疫组化、Real time-PCR, Western blot对比研究了两组着床窗口期HOXA10、LPAR3和COX2的表达情况,以探讨改良超长方案是否能通过改善PCOS患者的子宫内膜的容受性来提高IVF妊娠率。
由于PCOS患者体内FSH水平低,导致2-8mm小卵泡的堆积[2],并且FSH的阈值窄,这部分患者接受常规IVF助孕治疗,较其他患者更易发生OHSS(高达14%)[6]。卵母细胞体外成熟培养(In vitro maturation, IVM)是指从不孕妇女卵巢中获取未成熟卵子并体外培养成熟,再结合卵胞浆内精子注射治疗不孕症的辅助生殖技术。IVM技术可以在不使用或仅少量使用促性腺激素(Gn)的情况下获得卵子进行IVM,由于未用Gn或Gn用量小,即使注射人类绒毛膜促性腺激素(hCG),在治疗过程中患者体内的雌激素水平较低,不会达到诱发OHSS发生的水平而使OHSS发生率大大降低,同时因为使用药物少可以大幅度降低治疗费用。由于采用IVM技术治疗PCOS并发症少、费用低,部分中心使用IVM作为PCOS患者IVF治疗的一个替代途径。但是常规的IVM技术成功率较低,仅10%-30%,严重地限制了该技术在临床的广泛开展。在论文的第三部分我们探讨对IVM技术进行改良,以提高IVM治疗的成功率,以期为PCOS患者提供更安全有效的治疗方案。
第一部分改良超长方案在PCOS不孕患者IVF/ICSI-ET中的疗效
目的：分别回顾性和前瞻性比较改良超长方案降调节结合人绝经期促性腺激素(HMG)和常规长效长方案降调节在多囊卵巢综合征(PCOS)不孕患者行体外受精/胞浆内单精子注射-胚胎移植术(IVF/ICSI-ET)助孕中的疗效。
方法：(1)回顾分析我院2008.1-2012.12采用改良超长方案的1989例和长效长方案的1370例PCOS患者,对两组受精率、卵裂率、临床妊娠率、种植率、抱婴率、流产率、治疗费用等重要指标进行统计和对比。
(2)将我院2011.9～2012.4行IVF/ICSI-ET的PCOS患者随机分为两组,分别实施改良超长方案降调后促排卵(n=75)和标准的长效长方案促排(n=72)；观察两种促排方案的平均获卵数、受精率、优胚率、取消率、重度OHSS发生率、移植妊娠率、种植率、流产率、宫外孕率及其他相关指标,同时评价HCG日E2、LH、P、P/E2的水平,阴道超声检测两组患者HCG日子宫内膜(EM)的厚度、形态、血流情况,并将两组的结果进行对比分析。
结果：
(1)在回顾性研究中,改良超长方案组和长效长方案组在年龄、基础体重指数(BMI)、不孕年限、基础内分泌水平、平均获卵数、优胚率、移植的胚胎数、周期取消率、OHSS取消率、冻胚妊娠率、重度OHSS发生率差异均无明显差异(P>0.05)。但是改良超长方案组妊娠率为74.56%,胚胎种植率为52.51%,抱婴率60.43%,显著高于长效长方案组(分别妊娠率为56.02%,胚胎种植率为37.83%,抱婴率42.88%,P<0.001)。改良超长方案注射hCG日的P水平0.62±0.29ng/ml,明显低于长效长方案组(0.81±0.39ng/ml,P<0.05),而hCG日内膜厚度则明显厚于长效长方案组(12.26±2.42mm和11.36±2.43mm,P<0.001)。改良超长方案的早期流产率较长效长方案组明显下降(6.02%和8.59%,P<0.05)。此外,改良超长方案组的整体治疗费用较长效长方案组亦有显著下降(989.58±418.59元和5831.73±2313.13元,P<0.001)。
(2)在前瞻性研究中,两组患者共入选147例,无一例患者脱失。其中改良超长方案组75例,长效长方案组72例。两组患者相比其Gn用量(IU)、用药时间(天)、hCG日E2水平和LH水平、平均获卵数(个)、受精率、优胚率、取消率、移植胚胎数、重度OHSS发生率、流产率、宫外孕发生率均无统计学差异。改良超长方案组种植率及移植妊娠率(59.6%和77.9%)均高于长效长方案组(44.1%和61.3%,P<0.05)。与长效长方案相比,运用改良的超长方案促排后患者HCG日P水平及P/E2明显降低,子宫内膜(EM)的厚度、形态、血流情况明显改善。
结论：对PCOS不孕患者实施IVF/ICSI-ET助孕过程中,采用改良的GnRH-a超长降调节+hMG超排方案可通过优化患者内膜形态及血流分布,增加子宫内膜厚度,抑制子宫内膜过早的向分泌期转化等显著改善PCOS患者的子宫内膜的容受性,提高患者的着床率和妊娠率,并节约临床治疗费用。
第二部分改良超长方案对PCOS不孕患者着床期子宫内膜容受性的影响
目的：改良超长方案和长效长方案治疗PCOS患者着床期子宫内膜胞饮突、HOXA10、LPAR3、COX2表达的对比研究。
方法：分别收集改良超长方案组和长效长方案组治疗PCOS患者因OHSS原因取消移植后,取卵后第6天的子宫内膜组织,用电镜、Real time-RCR和Western blot、免疫组化方法观察两组的内膜组织胞饮突分布以及HOXA10、LPAR3、COX2基因的表达变化。
结果：
(1)改良超长方案组在取卵后第6天子宫内膜上出现大量呈蘑菇状、表面光滑、边界清楚的完全发育胞饮突形态。长效长方案组在取卵后6天出现胞饮突的数量少于改良超长方案组,很多呈局灶样分布,表面不光滑,多为微绒毛所覆盖,可见少量退化的胞饮突。
(2)在改良超长方案组和长效长方案组中所采取的子宫内膜上均有LPAR3、COX2、HOXA10的表达。但在着床期改良超长方案组子宫内膜LPAR3、COX2、HOXA10的表达水平显著高于长效长方案组。
结论：
改良超长方案通过增加着床期子宫内膜上的胞饮突的出现,增强着床相关因子LPAR3、COX2、HOXA10的表达,改善了子宫内膜的容受性。
第三部分不同的卵子体外成熟方案治疗PCOS患者的研究
目的：比较多囊卵巢综合征(PCOS)患者三种助孕方案：自然周期卵子体外成熟培养、降调节后短暂促性腺激素(Gn)刺激再IVM、长方案降调节后常规体外受精胚胎移植(IVF-ET)助孕治疗效果。
方法：前瞻性地将2010年1月至2012年12月在我院接受IVF助孕治疗的PCOS患者分别分入以下三组：A组(n=140),自然周期卵子体外成熟培养(IVM)；B组(n=152),降调节后短暂促性腺激素(Gn)刺激再IVM；C组(n=505),长方案降调节后常规体外受精胚胎移植(IVF-ET)助孕。比较三种助孕方案治疗效果。
结果：
(1)B组和C组临床妊娠率无明显统计学差异(B组为52.59%,C组为58.35%,P>0.05),但均明显高于A组(32.23%,P<0.05)。
(2)hCG日内膜厚度A组为5.99±1.96mm,B组为7.87+2.14mm,C组为11.81±2.20mm,三组比较均有统计学差异,P<0.05。优胚率A组为47.23±29.17,B组为59.95-30.43,C组为65.66-23.35,三组比较均有统计学差异,P<0.05。
(3)A组未使用Gn,B组Gn用量为600.08-291.21IU,费用为1868.11士1208.67元,C组Gn用量1776.36-693.76IU,费用5508.23-2193.17元,三组比较均有统计学差异(P<0.05)。
(4)A、B组无卵巢过度刺激综合征(OHSS)发生,C组重度OHSS发生率为2.18%。
结论：IVM助孕可以避免OHSS发生,若降调节后短暂Gn刺激再IVM助孕,优胚率更高,且由于子宫内膜发育得到改善,可以获得与长方案IVF相似的临床妊娠率,是PCOS患者的一个经济安全有效的助孕方式选择。
Polycystic Ovarian Syndrome (PCOS) is a common endocrinal disorder in women with non-ovulation infertility in childbearing age, its incidence is about5%in women of childbearing age.About80%PCOS women get pregnant through drug intervention or after laparoscopic ovarian drilling to induce normal ovulation. But there are still20%of the PCOS women require assisted reproductive technology (ART) to obtain pregnancy. In-vitro fertilization and embryo transfer (IVF-ET) is currently the most commonly-used technology, which taking the oocytes and the sperm outside the body and fertilizing them in vitro, and then culturing the zygote to early preimplantaion embryos and then transferring them back into the womb. A key step of a successful IVF-ET procedure is controlled ovarian hyperstimulation (COH), which inducing multiple follicular development and maturation in a controlled stimulation with exogenous drugs to get enough high quality oocytes, and generating multiple embryos for transfer per cycle to improve the pregnancy rate of IVF per cycle.
Long gonadotropin-releasing hormone-analogues (GnRH-a) down regulation is a commonly-used COH program for PCOS patients. But, PCOS patients are often accompanied with numerous endocrinal and metabolic abnormalities, such as:the insufficient secretion of FSH, increased secretion of LH, hyperinsulinemia, and hyperandrogenism, which leads to decreased IVF pregnancy rate and increased incidence of OHSS after COH. We wish to establish a more suitable COH program with higher pregnancy rate and decreased incidence of complication after COH. According to the pathological features of PCOS, we adopted a modified ultra-long down-regulation protocol. To answer whether our protocol improves the pregnancy rate in patients with PCOS, in the first part of this thesis, we retrospectively compared IVF outcomes of modified ultra-long protocol and routinely used long protocol for PCOS patients.
Good quality embryo needs to implant in the uterus, differentiation and eventually develop to a mature fetus. Implantation is another important step of a successful pregnancy. The endometrial receptivity, which refers to the endometrial ability to accept the embryo is a key aspect for a successful implantation.At present, there are several factors which affect the endometrial receptivity:the endometrial thickness, morphology, blood flow of endometrial, hormone levels, cytokines and genes which regulating uterine receptivity. All the factors interact as a network to regulate the receptivity and aid a successful implantation. In the implantation window, the endometrial thickness increases to above9mm, blood flow index of endometrial increases, pinopodes appears and the up-regulated expression of endometrial receptivity related genes such as leukocyte inhibitory factor (LIF) and HOXA10gene. Therefore, in the second part of this thesis, to explore the influence of ultra-long protocol to the endometrial receptivity, we examined emdometrial pinopodes by electron microscopy in the PCOS patients during the implantation window from both long protocol group and the modified ultra-long protocol group, we examined the expression of HOXA10, LPAR3and COX2in two groups with immunohistochemistry, realtime-PCR, Western blot. We attempts to answer whether modified ultra-long protocol generates better clinical outcomes by improving the endometrial receptivity as compared to long protocol group.
Because of the low FSH level in PCOS patients which leads to accumulation of small follicles with2-8mm diameter and the narrow FSH threshold, PCOS patients are much easier to suffer from ovarian hyperstimulation syndrome (OHSS) in routine COH protocols than non-PCOS patients. The incidence of OHSS in PCOS patients is up to14%. In vitro maturation (IVM) is a novel treatment for PCOS patients, which collects immature oocytes from infertile women without or with small dose of exogenous gonadotropin stimulation, the immature oocytes are then matured in vitro and fertilized by intracytoplasmic sperm injection (ICSI). Under this circumstance, no or much less exogenous gonadotropin (Gn) is needed to generate enough oocytes for late FVF-ET, the serum estrogen level is low in IVM patient which prevent the occurrence of OHSS after injection of HCG. Meanwhile, less usage of exogenous Gn dramatically decrease the cost for a fresh ET cycle. Due to the cost and less incidence of complications, IVM is adopted by some center to be alternative procedure for PCOS patients underwent IVF treatment. Due to the success rate of conventional IVM is10-30%, much lower than routine IVF, its clinical application is restricted. In part three of the thesis, we explored the possibility of improving the efficiency of IVM program in PCOS patients, trying to establish a safe but more effective strategy.
Part I. Study of modified ultra-long protocol in patients with PCOS in IVF/ICSI-ET
Objective:To retrospectively and prospectively compare clinical outcomes between modified ultra-long protocol down regulation in combination with human menopausal gonadotropin (hMG) and conventional long protocol down regulation in PCOS infertile women undergoing in vitro fertilization/intracytoplasmic sperm injection and embryo transfer (IVF/ICSI-ET).
Methods:(1) We retrospectively analyze the clinical data of1989PCOS patients received modified ultra-long protocol treatment and1370PCOS patients received routine down-regulation long protocol during January2008to December2012. The fertilization rate, implantation rate, pregnancy rate, lives birth rate, abortion rate and treatment cost were compared between the two groups.(2) PCOS patients who underwent IVF/ICSI-ET treatment from September2011to April2012in our hospital were divided into two groups:ultra-long protocol group (n=75) and long protocol group(n=72). The average number of retrieved oocytes, fertilization rate, implantation rate, pregnancy rate, abortion rate, thickness, morphology and pulsed Doppler study of uterine artery of endometrial on the day of hCG administration and the day of ET were detected and assessed by Doppler ultrasound and compared. Otherwise, the related indexes of two groups such as serum progestogen, estradiol and luteinizing hormone level and P/E2on hCG day were compared.
Results:(1) In the retrospective study, there were no significant differences in average age, body mass index, average infertility duration, basal FSH and LH level, average oocyte number, good-quality-embryo formation rate, average transferred embryos, cancellation rate, severe OHSS incidence between ultra-long protocol and long protocol. But the clinical pregnancy rate, implantation rate and take-home-baby rate in ultra-long protocol (74.56%,52.51%and60.43%, respectively) are much higher than in long protocol (56.02%,37.83%and42.88%, respectively). In ultra-long protocol, the serum P level on the day of hCG injection is lower than in long protocol (0.62±0.29ng/ml vs.0.81±0.39ng/ml, P<0.05), and the endometrial thickness is higher than in long protocol (12.26±2.42mm vs.11.36±2.43mm, P<0.001). The early abortion rate in ultra-long protocol is reduced than in long protocol (6.02%和8.59%, P<0.05). In addition, the average overall cost for ultra-long protocol is significantly reduced than for long protocol (989.58±418.59and5831.73±2313.13, P<0.001).(2) Totally147patients were included in the prospective study,75patients were in ultra-long protocol and72patients were in long protocol. The average Gn usage, duration for Gn, serum E2and LH level on day of hCG injection, average oocyte, fertilization rate, good quality embryo rate, cancellation rate, average transferred embryos, severe OHSS incidence, abortion rate showed no significant difference. But in ultra-long protocol, the clinical pregnancy rate per transfer cycle and the implantation rate were significantly higher than in long protocol (77.9%and59.6%vs.61.3%and44.1%,P<0.05). Compared to patients in long protocol, the patients in ultra-long protocol had lower serum P level on the day of hCG injection, and had better endometrial thickness, improved morphorlogy and blood flow.
Conclusion:Modified ultra-long protocol combined with hMG could improve the implantation rate and the clinical pregnancy rate for PCOS patients underwent IVF-ET treatment through increasing the endometrial thickness, promoting endometrial morphology transition and blood flow.
Part II Effect of modified ultra-long protocol on endometrium receptivity of PCOS patients
Objective:Comparatively study the morphology of endometrium pinopodes, the expression of HOXA10, LPAR3and COX2in PCOS patients in modified ultra-long protocol and long protocol.
Methods:Separately collect day6endometrium after oocyte retrieval from PCOS patients who underwent IVF/ICSI-ET treatment in either ultra-long protocol or long protocol, and quit the fresh embryo transfer due to OHSS risk. The expression of HOXA10, LPAR3and COX2in two groups was determined by immunohistochemistry, Real time-PCR, Western blot, and pinopodes were observed and analyzed by electron microscopy.
Results:We detected more uniform distribution of a fully developed pinopodes in the endometrium of patients in modified ultra-long protocol than in long protocol, which exhibited a large number mushroom like structure with smooth surface, clear boundary and membrane protrusions. And in the group of long protocol, the pinopodes distribute focally, the surface is not smooth, much of them covered with microvilli. The expression of implantation related factors LPAR3, COX2and HOXA10were higher in the endometrium from modified ultra-long protocol group than in the endometrium from long protocol group in either mRNA level and protein level during the period of implantation widow.
Conclusion:Modified ultra-long protocol may improve the endometrium receptivity through increasing pinopodes generation and LPAR3, COX2and HOXA10expression.
Part Ⅲ Study on different in vitro maturation treatments for PCOS patients
Objetive:To compare the clinical outcomes among IVM, low dose gonadotrophin stimulate IVM and long protocol in women with PCOS and find a safer and more effective treatment protocol for these patients
Methods:PCOS patients in our hospital from Jan.2010to.Dec.2012.were divided into three groups prospectively. Group A (n=140), routine IVM; Group B (n=152), low dose gonadotrophin stimulate IVM and Group C (n=505), long protocol group. The clinical outcomes of these three groups were compared.
Results:(1) The clinical pregnancy rates of group B and group C showed no significant differences (52.59%and58.35%, respectively, P>0.05) and were significantly higher than that in group A (32.23%, P<0.05).(2) The thickness of endometrial on the day of hCG injection in group A, B and C were5.99±1.96mm,7.87±2.14mm and11.81±2.20mm, showed significantly differences, P<0.05. At the same time, there were statistical significant for high-quality embryo rate in groupA、B and C(47.23±29.17vs.59.95±30.43vs.65.66±23.35, P<0.05).(3) There were significantly differences in the usage of Gn, no usage in group A, and the dosage of Gn in group B were600.08±291.21IU and the cost were1868.11±1208.67yuan. The dosage of Gn in group C were1776.36±693.76IU and the cost were5508.23±2193.17yuan (P<0.05)(4) There were no OHSS in group A^B, the severe OHSS rate in group C were2.18%.
Conclusion:IVM can avoid occurance of OHSS. The low dosage stimulation of Gn after down regulation then in vitro maturation can obtain similar clinical pregnancy rate compared to long protocol FVF due to improved endometrium. IVM is a safer and effective strategy for PCOS patients.
对于PCOS患者,临床上常规使用长效长方案进行促排卵。但是因PCOS患者往往伴有FSH分泌不足、LH分泌异常增高、高胰岛素血症、高雄激素血症等内分泌和代谢的异常,导致其IVF妊娠率低,促排后卵巢过度刺激综合征(Ovarian hyperstimulation syndrome, OHSS)等并发症发生率高[2]。对PCOS这一特殊人群,我们想找到一种更适合的促排卵方案,以获得更高的妊娠率、并减少促排卵并发症发生的风险。针对PCOS患者特殊的病理特征,我们前期发明了—种改良的超长方案。为了回答改良的超长方案是否可以提高PCOS患者的IVF妊娠率这一问题,在本论文的第一部分,我们分别通过回顾性和前瞻性的对照研究,比较了改良超长方案和长效长方案用于PCOS患者IVF治疗的各项临床指标和临床结局。
质量优良的胚胎在母体子宫内通过着床、分化,最终发育成一个成熟的胎儿。着床是建立成功妊娠的重要一步,而子宫内膜的容受性即子宫内膜接受胚胎的能力是着床的关键因素之一[3]。目前的观点认为,调节子宫内膜的容受性比较明确的指标有：子宫内膜的厚度、形态、血流,体内性激素水平,子宫内膜着床相关因子(如同源框基因相关蛋白产物和白细胞抑制因子)等。各个因素相互调节、作用,增加子宫内膜的容受性,使胚胎能够成功的植入。在人类着床窗口期,如子宫内膜厚度增加(>9mm)、内膜下血流指数上升、胞饮突出现、LIF、HOXA10基因等表达增加,则意味着良好的子宫内膜容受性[4、5]。因此,在本文的第二部分,为了探讨两种促排方案对子宫内膜容受性的影响,我们通过电镜检测了改良超长方案组和长效长方案组中PCOS患者着床窗口期胞饮突情况,用免疫组化、Real time-PCR, Western blot对比研究了两组着床窗口期HOXA10、LPAR3和COX2的表达情况,以探讨改良超长方案是否能通过改善PCOS患者的子宫内膜的容受性来提高IVF妊娠率。
由于PCOS患者体内FSH水平低,导致2-8mm小卵泡的堆积[2],并且FSH的阈值窄,这部分患者接受常规IVF助孕治疗,较其他患者更易发生OHSS(高达14%)[6]。卵母细胞体外成熟培养(In vitro maturation, IVM)是指从不孕妇女卵巢中获取未成熟卵子并体外培养成熟,再结合卵胞浆内精子注射治疗不孕症的辅助生殖技术。IVM技术可以在不使用或仅少量使用促性腺激素(Gn)的情况下获得卵子进行IVM,由于未用Gn或Gn用量小,即使注射人类绒毛膜促性腺激素(hCG),在治疗过程中患者体内的雌激素水平较低,不会达到诱发OHSS发生的水平而使OHSS发生率大大降低,同时因为使用药物少可以大幅度降低治疗费用。由于采用IVM技术治疗PCOS并发症少、费用低,部分中心使用IVM作为PCOS患者IVF治疗的一个替代途径。但是常规的IVM技术成功率较低,仅10%-30%,严重地限制了该技术在临床的广泛开展。在论文的第三部分我们探讨对IVM技术进行改良,以提高IVM治疗的成功率,以期为PCOS患者提供更安全有效的治疗方案。
第一部分改良超长方案在PCOS不孕患者IVF/ICSI-ET中的疗效
目的：分别回顾性和前瞻性比较改良超长方案降调节结合人绝经期促性腺激素(HMG)和常规长效长方案降调节在多囊卵巢综合征(PCOS)不孕患者行体外受精/胞浆内单精子注射-胚胎移植术(IVF/ICSI-ET)助孕中的疗效。
方法：(1)回顾分析我院2008.1-2012.12采用改良超长方案的1989例和长效长方案的1370例PCOS患者,对两组受精率、卵裂率、临床妊娠率、种植率、抱婴率、流产率、治疗费用等重要指标进行统计和对比。
(2)将我院2011.9～2012.4行IVF/ICSI-ET的PCOS患者随机分为两组,分别实施改良超长方案降调后促排卵(n=75)和标准的长效长方案促排(n=72)；观察两种促排方案的平均获卵数、受精率、优胚率、取消率、重度OHSS发生率、移植妊娠率、种植率、流产率、宫外孕率及其他相关指标,同时评价HCG日E2、LH、P、P/E2的水平,阴道超声检测两组患者HCG日子宫内膜(EM)的厚度、形态、血流情况,并将两组的结果进行对比分析。
结果：
(1)在回顾性研究中,改良超长方案组和长效长方案组在年龄、基础体重指数(BMI)、不孕年限、基础内分泌水平、平均获卵数、优胚率、移植的胚胎数、周期取消率、OHSS取消率、冻胚妊娠率、重度OHSS发生率差异均无明显差异(P>0.05)。但是改良超长方案组妊娠率为74.56%,胚胎种植率为52.51%,抱婴率60.43%,显著高于长效长方案组(分别妊娠率为56.02%,胚胎种植率为37.83%,抱婴率42.88%,P<0.001)。改良超长方案注射hCG日的P水平0.62±0.29ng/ml,明显低于长效长方案组(0.81±0.39ng/ml,P<0.05),而hCG日内膜厚度则明显厚于长效长方案组(12.26±2.42mm和11.36±2.43mm,P<0.001)。改良超长方案的早期流产率较长效长方案组明显下降(6.02%和8.59%,P<0.05)。此外,改良超长方案组的整体治疗费用较长效长方案组亦有显著下降(989.58±418.59元和5831.73±2313.13元,P<0.001)。
(2)在前瞻性研究中,两组患者共入选147例,无一例患者脱失。其中改良超长方案组75例,长效长方案组72例。两组患者相比其Gn用量(IU)、用药时间(天)、hCG日E2水平和LH水平、平均获卵数(个)、受精率、优胚率、取消率、移植胚胎数、重度OHSS发生率、流产率、宫外孕发生率均无统计学差异。改良超长方案组种植率及移植妊娠率(59.6%和77.9%)均高于长效长方案组(44.1%和61.3%,P<0.05)。与长效长方案相比,运用改良的超长方案促排后患者HCG日P水平及P/E2明显降低,子宫内膜(EM)的厚度、形态、血流情况明显改善。
结论：对PCOS不孕患者实施IVF/ICSI-ET助孕过程中,采用改良的GnRH-a超长降调节+hMG超排方案可通过优化患者内膜形态及血流分布,增加子宫内膜厚度,抑制子宫内膜过早的向分泌期转化等显著改善PCOS患者的子宫内膜的容受性,提高患者的着床率和妊娠率,并节约临床治疗费用。
第二部分改良超长方案对PCOS不孕患者着床期子宫内膜容受性的影响
目的：改良超长方案和长效长方案治疗PCOS患者着床期子宫内膜胞饮突、HOXA10、LPAR3、COX2表达的对比研究。
方法：分别收集改良超长方案组和长效长方案组治疗PCOS患者因OHSS原因取消移植后,取卵后第6天的子宫内膜组织,用电镜、Real time-RCR和Western blot、免疫组化方法观察两组的内膜组织胞饮突分布以及HOXA10、LPAR3、COX2基因的表达变化。
结果：
(1)改良超长方案组在取卵后第6天子宫内膜上出现大量呈蘑菇状、表面光滑、边界清楚的完全发育胞饮突形态。长效长方案组在取卵后6天出现胞饮突的数量少于改良超长方案组,很多呈局灶样分布,表面不光滑,多为微绒毛所覆盖,可见少量退化的胞饮突。
(2)在改良超长方案组和长效长方案组中所采取的子宫内膜上均有LPAR3、COX2、HOXA10的表达。但在着床期改良超长方案组子宫内膜LPAR3、COX2、HOXA10的表达水平显著高于长效长方案组。
结论：
改良超长方案通过增加着床期子宫内膜上的胞饮突的出现,增强着床相关因子LPAR3、COX2、HOXA10的表达,改善了子宫内膜的容受性。
第三部分不同的卵子体外成熟方案治疗PCOS患者的研究
目的：比较多囊卵巢综合征(PCOS)患者三种助孕方案：自然周期卵子体外成熟培养、降调节后短暂促性腺激素(Gn)刺激再IVM、长方案降调节后常规体外受精胚胎移植(IVF-ET)助孕治疗效果。
方法：前瞻性地将2010年1月至2012年12月在我院接受IVF助孕治疗的PCOS患者分别分入以下三组：A组(n=140),自然周期卵子体外成熟培养(IVM)；B组(n=152),降调节后短暂促性腺激素(Gn)刺激再IVM；C组(n=505),长方案降调节后常规体外受精胚胎移植(IVF-ET)助孕。比较三种助孕方案治疗效果。
结果：
(1)B组和C组临床妊娠率无明显统计学差异(B组为52.59%,C组为58.35%,P>0.05),但均明显高于A组(32.23%,P<0.05)。
(2)hCG日内膜厚度A组为5.99±1.96mm,B组为7.87+2.14mm,C组为11.81±2.20mm,三组比较均有统计学差异,P<0.05。优胚率A组为47.23±29.17,B组为59.95-30.43,C组为65.66-23.35,三组比较均有统计学差异,P<0.05。
(3)A组未使用Gn,B组Gn用量为600.08-291.21IU,费用为1868.11士1208.67元,C组Gn用量1776.36-693.76IU,费用5508.23-2193.17元,三组比较均有统计学差异(P<0.05)。
(4)A、B组无卵巢过度刺激综合征(OHSS)发生,C组重度OHSS发生率为2.18%。
结论：IVM助孕可以避免OHSS发生,若降调节后短暂Gn刺激再IVM助孕,优胚率更高,且由于子宫内膜发育得到改善,可以获得与长方案IVF相似的临床妊娠率,是PCOS患者的一个经济安全有效的助孕方式选择。
Polycystic Ovarian Syndrome (PCOS) is a common endocrinal disorder in women with non-ovulation infertility in childbearing age, its incidence is about5%in women of childbearing age.About80%PCOS women get pregnant through drug intervention or after laparoscopic ovarian drilling to induce normal ovulation. But there are still20%of the PCOS women require assisted reproductive technology (ART) to obtain pregnancy. In-vitro fertilization and embryo transfer (IVF-ET) is currently the most commonly-used technology, which taking the oocytes and the sperm outside the body and fertilizing them in vitro, and then culturing the zygote to early preimplantaion embryos and then transferring them back into the womb. A key step of a successful IVF-ET procedure is controlled ovarian hyperstimulation (COH), which inducing multiple follicular development and maturation in a controlled stimulation with exogenous drugs to get enough high quality oocytes, and generating multiple embryos for transfer per cycle to improve the pregnancy rate of IVF per cycle.
Long gonadotropin-releasing hormone-analogues (GnRH-a) down regulation is a commonly-used COH program for PCOS patients. But, PCOS patients are often accompanied with numerous endocrinal and metabolic abnormalities, such as:the insufficient secretion of FSH, increased secretion of LH, hyperinsulinemia, and hyperandrogenism, which leads to decreased IVF pregnancy rate and increased incidence of OHSS after COH. We wish to establish a more suitable COH program with higher pregnancy rate and decreased incidence of complication after COH. According to the pathological features of PCOS, we adopted a modified ultra-long down-regulation protocol. To answer whether our protocol improves the pregnancy rate in patients with PCOS, in the first part of this thesis, we retrospectively compared IVF outcomes of modified ultra-long protocol and routinely used long protocol for PCOS patients.
Good quality embryo needs to implant in the uterus, differentiation and eventually develop to a mature fetus. Implantation is another important step of a successful pregnancy. The endometrial receptivity, which refers to the endometrial ability to accept the embryo is a key aspect for a successful implantation.At present, there are several factors which affect the endometrial receptivity:the endometrial thickness, morphology, blood flow of endometrial, hormone levels, cytokines and genes which regulating uterine receptivity. All the factors interact as a network to regulate the receptivity and aid a successful implantation. In the implantation window, the endometrial thickness increases to above9mm, blood flow index of endometrial increases, pinopodes appears and the up-regulated expression of endometrial receptivity related genes such as leukocyte inhibitory factor (LIF) and HOXA10gene. Therefore, in the second part of this thesis, to explore the influence of ultra-long protocol to the endometrial receptivity, we examined emdometrial pinopodes by electron microscopy in the PCOS patients during the implantation window from both long protocol group and the modified ultra-long protocol group, we examined the expression of HOXA10, LPAR3and COX2in two groups with immunohistochemistry, realtime-PCR, Western blot. We attempts to answer whether modified ultra-long protocol generates better clinical outcomes by improving the endometrial receptivity as compared to long protocol group.
Because of the low FSH level in PCOS patients which leads to accumulation of small follicles with2-8mm diameter and the narrow FSH threshold, PCOS patients are much easier to suffer from ovarian hyperstimulation syndrome (OHSS) in routine COH protocols than non-PCOS patients. The incidence of OHSS in PCOS patients is up to14%. In vitro maturation (IVM) is a novel treatment for PCOS patients, which collects immature oocytes from infertile women without or with small dose of exogenous gonadotropin stimulation, the immature oocytes are then matured in vitro and fertilized by intracytoplasmic sperm injection (ICSI). Under this circumstance, no or much less exogenous gonadotropin (Gn) is needed to generate enough oocytes for late FVF-ET, the serum estrogen level is low in IVM patient which prevent the occurrence of OHSS after injection of HCG. Meanwhile, less usage of exogenous Gn dramatically decrease the cost for a fresh ET cycle. Due to the cost and less incidence of complications, IVM is adopted by some center to be alternative procedure for PCOS patients underwent IVF treatment. Due to the success rate of conventional IVM is10-30%, much lower than routine IVF, its clinical application is restricted. In part three of the thesis, we explored the possibility of improving the efficiency of IVM program in PCOS patients, trying to establish a safe but more effective strategy.
Part I. Study of modified ultra-long protocol in patients with PCOS in IVF/ICSI-ET
Objective:To retrospectively and prospectively compare clinical outcomes between modified ultra-long protocol down regulation in combination with human menopausal gonadotropin (hMG) and conventional long protocol down regulation in PCOS infertile women undergoing in vitro fertilization/intracytoplasmic sperm injection and embryo transfer (IVF/ICSI-ET).
Methods:(1) We retrospectively analyze the clinical data of1989PCOS patients received modified ultra-long protocol treatment and1370PCOS patients received routine down-regulation long protocol during January2008to December2012. The fertilization rate, implantation rate, pregnancy rate, lives birth rate, abortion rate and treatment cost were compared between the two groups.(2) PCOS patients who underwent IVF/ICSI-ET treatment from September2011to April2012in our hospital were divided into two groups:ultra-long protocol group (n=75) and long protocol group(n=72). The average number of retrieved oocytes, fertilization rate, implantation rate, pregnancy rate, abortion rate, thickness, morphology and pulsed Doppler study of uterine artery of endometrial on the day of hCG administration and the day of ET were detected and assessed by Doppler ultrasound and compared. Otherwise, the related indexes of two groups such as serum progestogen, estradiol and luteinizing hormone level and P/E2on hCG day were compared.
Results:(1) In the retrospective study, there were no significant differences in average age, body mass index, average infertility duration, basal FSH and LH level, average oocyte number, good-quality-embryo formation rate, average transferred embryos, cancellation rate, severe OHSS incidence between ultra-long protocol and long protocol. But the clinical pregnancy rate, implantation rate and take-home-baby rate in ultra-long protocol (74.56%,52.51%and60.43%, respectively) are much higher than in long protocol (56.02%,37.83%and42.88%, respectively). In ultra-long protocol, the serum P level on the day of hCG injection is lower than in long protocol (0.62±0.29ng/ml vs.0.81±0.39ng/ml, P<0.05), and the endometrial thickness is higher than in long protocol (12.26±2.42mm vs.11.36±2.43mm, P<0.001). The early abortion rate in ultra-long protocol is reduced than in long protocol (6.02%和8.59%, P<0.05). In addition, the average overall cost for ultra-long protocol is significantly reduced than for long protocol (989.58±418.59and5831.73±2313.13, P<0.001).(2) Totally147patients were included in the prospective study,75patients were in ultra-long protocol and72patients were in long protocol. The average Gn usage, duration for Gn, serum E2and LH level on day of hCG injection, average oocyte, fertilization rate, good quality embryo rate, cancellation rate, average transferred embryos, severe OHSS incidence, abortion rate showed no significant difference. But in ultra-long protocol, the clinical pregnancy rate per transfer cycle and the implantation rate were significantly higher than in long protocol (77.9%and59.6%vs.61.3%and44.1%,P<0.05). Compared to patients in long protocol, the patients in ultra-long protocol had lower serum P level on the day of hCG injection, and had better endometrial thickness, improved morphorlogy and blood flow.
Conclusion:Modified ultra-long protocol combined with hMG could improve the implantation rate and the clinical pregnancy rate for PCOS patients underwent IVF-ET treatment through increasing the endometrial thickness, promoting endometrial morphology transition and blood flow.
Part II Effect of modified ultra-long protocol on endometrium receptivity of PCOS patients
Objective:Comparatively study the morphology of endometrium pinopodes, the expression of HOXA10, LPAR3and COX2in PCOS patients in modified ultra-long protocol and long protocol.
Methods:Separately collect day6endometrium after oocyte retrieval from PCOS patients who underwent IVF/ICSI-ET treatment in either ultra-long protocol or long protocol, and quit the fresh embryo transfer due to OHSS risk. The expression of HOXA10, LPAR3and COX2in two groups was determined by immunohistochemistry, Real time-PCR, Western blot, and pinopodes were observed and analyzed by electron microscopy.
Results:We detected more uniform distribution of a fully developed pinopodes in the endometrium of patients in modified ultra-long protocol than in long protocol, which exhibited a large number mushroom like structure with smooth surface, clear boundary and membrane protrusions. And in the group of long protocol, the pinopodes distribute focally, the surface is not smooth, much of them covered with microvilli. The expression of implantation related factors LPAR3, COX2and HOXA10were higher in the endometrium from modified ultra-long protocol group than in the endometrium from long protocol group in either mRNA level and protein level during the period of implantation widow.
Conclusion:Modified ultra-long protocol may improve the endometrium receptivity through increasing pinopodes generation and LPAR3, COX2and HOXA10expression.
Part Ⅲ Study on different in vitro maturation treatments for PCOS patients
Objetive:To compare the clinical outcomes among IVM, low dose gonadotrophin stimulate IVM and long protocol in women with PCOS and find a safer and more effective treatment protocol for these patients
Methods:PCOS patients in our hospital from Jan.2010to.Dec.2012.were divided into three groups prospectively. Group A (n=140), routine IVM; Group B (n=152), low dose gonadotrophin stimulate IVM and Group C (n=505), long protocol group. The clinical outcomes of these three groups were compared.
Results:(1) The clinical pregnancy rates of group B and group C showed no significant differences (52.59%and58.35%, respectively, P>0.05) and were significantly higher than that in group A (32.23%, P<0.05).(2) The thickness of endometrial on the day of hCG injection in group A, B and C were5.99±1.96mm,7.87±2.14mm and11.81±2.20mm, showed significantly differences, P<0.05. At the same time, there were statistical significant for high-quality embryo rate in groupA、B and C(47.23±29.17vs.59.95±30.43vs.65.66±23.35, P<0.05).(3) There were significantly differences in the usage of Gn, no usage in group A, and the dosage of Gn in group B were600.08±291.21IU and the cost were1868.11±1208.67yuan. The dosage of Gn in group C were1776.36±693.76IU and the cost were5508.23±2193.17yuan (P<0.05)(4) There were no OHSS in group A^B, the severe OHSS rate in group C were2.18%.
Conclusion:IVM can avoid occurance of OHSS. The low dosage stimulation of Gn after down regulation then in vitro maturation can obtain similar clinical pregnancy rate compared to long protocol FVF due to improved endometrium. IVM is a safer and effective strategy for PCOS patients.
引文
[1]Lavenue JS, Imani B, Eijkenmans MJ, et al. New approaches to PCOS and other forms of anovlation[J]. Obstet Gynecol Surv:2002,57(2):755-767.
[2]Franks S, Stark J, Hardy K. Follicle dynamics and anovulation in polycystic ovary syndrome[J]. Hum Reprod Update:2008,14(4):367-378.
[3]Achache H, Revel A. Endometrial receptivity markers,the journey to successful embryo implantation[J].Hum Reprod Update:2006,12(6):731-746.
[4]陈骞,孙海翔,胡娅莉,等.子宫内膜厚度对体外受精-胚胎移植治疗结局的影响[J].生殖与避孕,2008,28(12)：730-733.
[5]Jarvela IY, Sladkevidius P, Kelly S, et al. Evaluation of endometrial receptivity during in-vitro fertiliazation using three-dimensional power Doppler ultrasound. Ultrasound Obstet Gynencol[J].2005,26(7):765-769.
[6]邵明君,叶碧绿,赵军招,等.体外受精-胚胎移植在多囊卵巢综合征不育患者中的应用[J].生殖医学杂志,2005,14(1)：10-12.
[7]高洪伟,张琳.影响PCOS女性IVF-ET结局的内分泌代谢因素及其药物干预[J].药品评价,2012,25(4)：19-23.
[8]张云山,张凤英,高企贤.LH在卵泡发育及卵巢刺激中的作用[J].国外医学(计划生育分册),2002,21(3)：12-16.
[9]Kurzawa R, Ciepiela P, Baczkowski T, et al. Comparison of embryological and clinical outcome in GnRH antagonist vs. GnRH agonist protocols for in vitro fertilization in PCOS non-obese patients. A prospective randomized study [J]. J Assist Reprod Genet,2008,25(8):365-374.
[10]Porter RN, Smith W, Craft L, et al. Induction of ovulation for in vitro fertilization using buserelin and gonadotropins [J]. Lancet,1984,2(8414): 1284-1285.
[11]Lainas TG, Sfontouris IA, Zorzovilis IZ, et al. Fleible GnRH antagonist protocol versus GnRH agonist long protocol in patients with polycystic ovary syndrome treated for IVF:a prospective randomized controlled trial (RCT)[J] Hum Reprod,2010,25(3):683-689.
[12]Palep-Singh M, Picton HM, Vrotsou K, et al. South asian women with polycystic ovary syndrome exhibit greater sensitivity to gonadotropin stimulation with reduced fertilization and ongoing pregnancy rates than their Caucasian counterparts [J]. Eur J Obstet Gynecol Reprod Bio, 2007,134(2):202-207.
[13]Thessaloniki ESHRE/ASRM-Sponsored PCOS Consensus workshop group. Consensus on infertility treatment related to polycystic ovary syndrome[J]. Hum Reprod,2008,23(3):462-477.
[14]Surrey MD, Kaylen M, Silverberg MD, et al. Effect of prolonged gonadotropin-releasing hormone agonist therapy on the outcome of in vitro fertilization-embryo transfer in patients with endometriosis[J]. Fertil Steril, 2002,78(4):699-704.
[15]Rickes D, Nickel I, Kropf S. Increased pregnancy rates after ultralong postoperative therapy with gonadotropin releasing hormone analogs in patients with endometriosis[J]. Fertil Steril,2002,78(4):757-762.
[16]徐仙,宋梦玲.子宫内膜容受性的临床应用的研究进展[J].宁夏医学杂志,2011,33(9)：799-802.
[17]Nardo LG, Sabatini L, Rai R, et al. Pinopode Expression During Human Implantation [J]. Eur Obstet Gyncol Reprod Biol,2002,101(2):104-108.
[18]Liatsikos SA, Grimbizis GF, Georgiou I,et al. HOXA10 and HOXA11 mutation scan in congenital malformations of the female genital tract [J]. Reprod Biomed Online,2010,21(1):126-132.
[19]Ye X, Hama K, Contos JJ. LPA3-mediated lysophosphatidic acid signalling in embryo implantation and spacing [J]. Nature,2005,435:104-108.
[20]Kotaro H, Junken A, Koji B:Lysophosphatidic receptor, LPA3, is positively and negatively regulated by progesterone and estrogen in the mouse uterus [J]. Life Sciences,2006,79:1736-1740.
[21]Katarzyna K, Marta W, Iona B:Quantitative expression of lysophosphatidic acid receptor 3 gene in porcine endometrium during the periimplantation period and estrous cycle [J]. Prostaglandins other lipid mediators,2008,85:26-32.
[22]Hanna A, Avi T, Diana P:Defective endometrial prostaglandin synthesis identified in patients with repeated implantation failure undergoing in vitro fertilization [J]. Fertility and Sterility,2010,94:1271-1278
[23]Qingxiang W, Teresa F, Pamela S:Reduced expression of biomarkers associated with the implantation window in women with endometriosis [J]. Fertility and Sterility 2009,91:1686-1691
[24]Cha KY, Koo JJ, Choi DH, et al. Pregnancy after in vitro fertilization of human follicular oocytes collected from non-stimulated cycles, their culture in vitro and their transfer in a donor oocyte program [J]. Fertil Steril,1991,55(2):109-113.
[25]Jaroudi KA, Hollanders JMG, Elnour AM, et al. Embryo development and pregnancies from in vitro matured and fertilized human oocytes [J]. Human Reproduction,1999,14(9):1749-1751
[26]Cobo AC, Requena A, Neuspiller F, et al. Navarro J. Maturation in vitroof human oocytes from unstimulated cycles:selection of the optimal day for ovum retrieval based on follicular size [J]. Human Reproduction,1999,14:1864-1868.
[27]Chian RC, Buckett WM, Tulandi T, et al. Prospective randomized study of human chorionic gonadotrophin priming before immature oocyte retrieval from unstimulated women with polycystic ovarian syndrome[J]. Human Reproduction,2000,15:150-170.
[28]Wynn P, Picton HM, Krapez JA, et al. Pretreatment with follicle stimulating hormone promotes the numbers of human oocytes reaching metaphase II by in vitro maturation[J]. Human Reproduction,1998,13:3132-3138.
[29]Li Yuan, Cheng ZiJiang, Zhao LiXin, et al. A case of clinic pregnacy after oocyte in vitro maturation and IVF-ET [J]. National Journal of Andrology, 2002,8:70-71.
[30]Heijnen EM, Eijkemans MJ, Hughes EG, et al. A meta-analysis of outcomes of conventional IVF in women with polycystic ovary syndrome [J]. Human Reproduction Update,2006,12(1):13-21.
[31]Balasch J, Fernandomez G, Casamitjana R, et al. Pituitary-ovarian suppression by the standard and half-doses of D-Trp-6-luteinizing hormone-releasing hormone depot [J]. Hum Reprod,1992,7(9):1230-1234
[32]李晓红,武学清,王嵩,等.减量促性腺激素释放激素激动剂在促排卵中的应用[J]. 生殖医学杂志,2003,12(3)：146-149.
[33]Ziecik AJ, Derecka-Reszka K and Rzucidlo SJ. Extragonadal gonadotropin receptors their distribution and function [J]. J Physiol Pharmacol,1992,4:33-49
[34]Pellatt L,Hanna L,Brincat M,et al. Granulosa cell production of anti-Mullerian hormone is increased in Polycystic Ovaries [J]. Journal of Clinical Endocrinology an Metabolism,2007,92:240-245
[35]邹燕琴,李红.多囊卵巢综合症患者自然流产的相关因素分析[J].国外医学计划生育分册.2004,23(4)：219-221
[36]Eman A. Elgindy, M.D. Progesterone level and progesterone/estradiol ratio on the day of hCG administration:detrimental cutoff levels and new treatment strategy[J]. Fertility and Sterility,2011,95(5):1639-1644.
[37]Ze Wu, Rong Li, Yanping Ma,Effect of HCG-day serum progesterone and oestradiol concentrations on pregnancy outcomes in GnRH agonist cycles [J]. Reproductive BioMedicine Online,2012,24 (5):511-520.
[38]Li R, Qiao J, Wang L, Zhen X, Lu Y. Serum progesterone concentration on day of HCG administration and IVF outcome [J]. Reprod Biomed Online. 2008;16(5):627-31
[39]Rickes D, Nickel I, Kropf S. Increased pregnancy rates after ultralong postoperative therapy with gonadotropin releasing hormone analogs in patients with endometriosis [J]. Fertil Steril,2002,78(4):757-762.
[40]Young KA, Chaffin CL, Molskness TA, et al., Controlled ovulation of the dominant follicle:a critical role for LH in the late follicular phase of the menstrual cycle [J].Hum. Reprod.2003,18:2257-2263.
[41]C.A.Venetis1, E.M.Kolibianakisl,3, E.Papanikolaou, et al., Is progesterone elevation on the day of human chorionic gonadotrophin administration associated with the probability of pregnancy in in vitro fertilization? A systematic review and meta-analysis [J]. Human Reproduction Update,2007, 13(4):343-355.
[42]Bosch E, Valencia I, Escudero E, Premature luteinization during gonadotropin-releasing hormone antagonist cycles and its relationship with in vitro fertilization outcome, [J] Fertility and Sterility,2003,80:1444-1449.
[43]Eman A. Elgindy, M.D. Progesterone level and progesterone/estradiol ratio on the day of hCG administration:detrimental cutoff levels and new treatment strategy [J]. Fertility and Sterility,2011,95(5):1639-1644.
[44]Ze Wu, Rong Li, Yanping Ma, Effect of HCG-day serum progesterone and oestradiol concentrations on pregnancy outcomes in GnRH agonist cycles [J].Reproductive BioMedicine Online,2012,24 (5):511-520.
[45]raoul Orvieto, Simion Meltcer, Gad Liberty, et al., Does day-3 LH/FSH ratio influence in vitro fertilization outcome PCOS patients undergoing controlled ovarian hyperstimulatio with different GnRH-analogue[J]? Gynecological Endocrinology,2012,28(6):422-424.
[46]Sharara FI.Lim J.McClamrock HD Endometrial pattern on the day of oocyte retrieval is more predictive of implantation success than the pattern or thickness on the day of hCG administration[J]. J Assist Reprod Genat.1999,16(101): 523-528.
[47]Xingqi Zhang, Chi-Huang Chen, Edmond Confino,et al.,Increased endometrial thickness is associated with improved treatment outcome for selected patients undergoing in vitro fertilization-embryo transfer [J].Fertility and Sterility,2005, 83(2):336-340.
[48]I. Y. J ARVELA, P. SLADKEVICIUS, S. KELLY, et al., Evaluation of endometrial receptivity during in-vitro fertilization using three-dimensional power Doppler ultrasound.[J].Ultrasound Obstet Gynecol,2005,26:765-769.
[49]Gonen Y, Casper RF. Prediction of implantation by the sonographic appearance of the endometrium during controlled ovarian stimulation for in vitro fertihzation [J]. J In Vitro Fert Embryo Trand,1990,7(3):146-152.
[50]A.M.E. Lintsen, P.C.M. Pasker-de Jong, E.J. de Boer, et al.Effects of subfertility cause, smoking and body weight on the success rate of IVF[J]. Human Reproduction 2005,20 (7):1867-1875
[51]Chien LW, Au HK, Chen PL, Xiao J, Tseng CR. Assessment of uterine receptivity by the endometrial-subendometrial blood flow distribution pattern in women undergoing in vitro fertilization-embryo transfer [J]. Fertility and Sterility 2002;78:245-51.
[52]Ernest Hung Yu Ng*, Carina Chi Wai Chan, Oi Shan Tang, et al., The role of endometrial blood flow measured by three-dimensional power Doppler ultrasound in the prediction of pregnancy during in vitro fertilization treatment [J].European Journal of Obstetrics & Gynecology and Reproductive Biology, 2007,135:8-16.
[53]Raine-Fenning NJ, Campbell BK, Kendall NR, Clewes JS, John-son IR. Quantifying the changes in endometrial vascularity throughout the normal menstrual cycle with three-dimensional power Doppler angiography [J]. Hum Reprod 2004; 19:330-338.
[54]Okuhue JE, Onuh SO, Ebeigbe P, Shaibu I, Wada I, et al., The effect of endometrial thickness on in vitro fertilization (IVF)-embryo transfer/ intracytoplasmic sperm injection (ICSI) outcome[J].Afr J Reprod Health,2009 13:113-121.
[55]Traub ML, Van Arsdale A, Pal L, Jindal S, Santoro N, Endometrial thickness, Caucasian ethnicity, and age predict clinical pregnancy following fresh blastocyst embryo transfer:a retrospective cohort [J].Reprod Biol Endocrinol 2009,7:33.
[56]Rashidi BH, Sadeghi M, Jafarabadi M, Tehrani Nejad ES, Relationships between pregnancy rates following in vitro fertilization or intracytoplasmic sperm injection and endometrial thickness and pattern[J].Eur J Obstet Gynaecol Reprod Biol,2005,120:179-184.
[57]Kinay T, Tasci Y, Dilbaz S, Cinar O, Demir B et al., The relationship between endometrial thickness and pregnancy rates in GnRH antagonist down-regulated ICSI cycles[J].Gynecol Endocrinol,2010,26:833-837.
[58]Emma Boys and Michael Chapman, The Influence of Endometrial Thickness on IVF Outcomes[J]. J Fert In Vitro,2012,2 (2):2-4.
[59]A.M.E. Lintsen, P.C.M. Pasker-de Jong, E.J. de Boer, et al.Effects of subfertility cause, smoking and body weight on the success rate of IVF [J]. Human Reproduction 2005,20 (7):1867-1875
[60]Emily S. Jungheim, Susan E. Lanzendorf, et al., Morbid obesity is associated with lower clinical pregnancy rates after in vitro fertilization in women with polycystic ovary syndrome[J]. Fertility and Sterility,2009,92(1):256-261.
[61]Megan L. Sneed, Meike L. Uhle, H. Edward Grotjan,et al., Body mass index: impact on IVF success appears age-related. [J] Human Reproduction,2008, 23(8):1835-1839.
[62]M Metwally, R Cutting, A Tipton, et al., Effect of increased body mass index on oocyte and embryo quality in IVF patients, Reproductive BioMedicine Online. [J].2007,15(5):532-538.
[63]Stavreus. Evers A, Nikas G, Sahlin L, et al. Formation of pinopodes in humau endometrium is associated with the concentrations of progesterone and progesterone receptors[J]. Ferlil Steril,2001,76(41):782-791.
[64]Hambartsoumian E. Endometrial leukemia inhibitory factor (LIF)as a possible cause of unexplained infertility and multiple failures of implantation[J]. Am J Reprod lmmunol,1998,39(2):137-142
[65]Psychoyos A, Mandon P. Scanning electron microscopy of the surface of the rat uterine epithelium during delayed implantation[J]. J Reprod Fertil,1971,26(1): 137-139
[66]Nikas G, Develioglu O H, Toner J P, et al. Endometrial Pinopodes Indicate A Shift in the Window Receptivity in IVF Cycles [J]. Hum Reprod,1994,14(3):787-792.
[67]Sunder S, Lenton EA. Endocrinology of the peri-implantation period[J]. Baillieres Best Pract Res Clin Obstet Gynaecol,2000,14(5):789-791
[68]Martel D, Monier M N, Roche D, et al. Hormonal Dependence of Pinopode Formation at the Uterine Luminal Surface [J]. Hum Reprod, 1991,6(4):597-603.
[69]Murthi P, Hiden U, Rajaraman G, et al. Novel homeobox genes are differentially expressed in placental microvascular endothelial cells compared with microvascular cells[J]. Placenta,2008,29(2):624-630.
[70]Wei Q, St Clair JB, Fu T, et al. Reduced expression of biomarkers associated with the implantation window in women with endometriosis [J]. Fertil Steril, 2009,91(3):1686-1691.
[71]Block K, Kardana A, Igarashi P, et al. In utero diethylstilbestrol(DES) exposure alters Hox gene expression in the developing mullerian system [J]. FASEB J,2000,14(3):1101-1108
[72]Salih SM, Taylor HS. HOXA10 gene expression in human fallopian tube and ectopic pregnancy [J]. Am J Obstet Gynecol,2004,190(7):1404-1406.
[73]Lee B, Du H, Tayler HS, Experimental murine endometriosis induces DNA methylation and altered gene expression in eutopic endometrium [J]. Biol Reprod,2009,80(7):79-85.
[74]Ye X. Jerold Chun. Lysophosphatidic Acid (LPA) signaling in vertebrate reproduction. Trends Endocrinol Metab.2010.21(1):17-26
[75]Guo Hui, Gong Fei, Luo Keli, LU guangxiu. Cyclic regulation of LPA3 in human endometrium [J]. Archives of Gynecology and Obstetrics,2012,7(18):321-324.
[76]Trounson A, Wood C, Kausche A.In vitro maturation and the fertilization and developmental competence of oocytes recoverd from untreated polycystic ovarian patients[J].Fertil Steril,1994,62 (2):353-362.
[77]Le Du A, Kadoch I.J, Bourcigaux N, et al.In vitro oocyte maturation for the treatment of infertility associated with polycystic ovarian syndrome.the French experience[J]. Hum Reprod,2005,20(2):420-424.
[78]Mikkelsen AL. Srtategies in human in-vitro maturation and their clnical outcome[J]. Reprod BioMed Online,2005,10(5):593-599.
[79]Chian RC, Bucket WM, Tulandi T, et al. Prospective randomized study of human chorionic gonadotrophin riming before immature oocyte retrieval from unstimulated women with polycystic ovarian syndrome[J]. Hum Reprod,2000, 15(1):165-170.
[80]Hreinsson J, Rosenlund B, Friden B, et al. Recombination LH is equally effective as recombinate HCG in promoting oocyte maturation in a clinical in-vitro maturation programme:a randomized study[J]. Hum Reprod,2003, 18(10):2131-2136.
[81]Child TJ, Abdul-Jalil AK, Gulekli B, et al. In vitro maturation and fertilization of oocytes from unstimulate dnormal ovaries, polycystic ovaries, and women with polycystic ovarysyndrome[J]. Fertil Steril,2001,76(5):936-942.
[82]Wynn P, Picton HM, Krapez JA, et al. Pretreatment with follicle stimulating hormone promotes the numbers of human oocytes reaching metaphase II by in-vitro maturation [J]. Hum Reprod,1998,13 (11):3132-3138.
[83]Cortvrindt R, Smitz J, Steirteghem ACV. In-vitro maturation, fertilization and embryo development of immature oocytes from early preantral follicles from prepuberal mice in a simplified culture system[J]. Hum Reprod, 1996,11(12):2656-2666.
[84]Child TJ, Sylvestre C, Pirwanyl, et al. Basal serum levels of FSH and estradiol in ovulatory and anovulatory women undergoing treatment by in-vitro maturation of immature oocytes[J]. Hum Reprod,2002,17 (8):1997-2002.
[85]Kim BK, Lee SC, Kim KJ, et al. In vitro maturation, fertilization, and development of human germinal vesicle oocytes collected from stimulated cycles[J]. Fertil Steril,2000,74(6):1153-1158.
[86]Mikkelsen AS, Smith SD & Lindenberg S. In-vitro maturation of human oocytes from regular menstruating women may be successful without follicoe stimulationg hormone priming[J]. Hum Reprod,1999,14(7):1847-1851.
[87]Noyes N, Liu HC, Sultan, K, et al. Endometrial thickness appears to be a significant factor in embryo implantation in in-vitro fertilization [J]. Hum Reprod,1995,10(4):919-922.
[88]Rinaldi L, Lisi F, Floccari A, et al. Endometrial thickness as a predictor of pregnancy after in-vitro fertilization but not after intra cytoplasmic sperm injection[J]. Hum Reprod,1996,11(7):1538-1541.
[89]Suikkari A-M, Tulppala M, Tuuri T, et al. Luteal phase start of low-dose FSH priming of follicles results in an effient recovery, maturation and fertilization of immature human oocytes[J]. Hum Reprod,2000,15(4):747-751.
[90]Schield RL, Knobloch C, Dorn C, et al. Endometrial receptivity in an in vitro fertilization program as assessed by spiral artery blood flow, endometrial thickness, endometrial volume,and uterine artery blood flow[J]. Fertil Steril, 2001,75(2):361-366.
[91]Child TJ, Phillips SJ, Abdul-Jalil AK, et al. A comparison of in vitro maturation and in vitro fertilization for women with polycystic ovaries[J]. Obstet Gynecol, 2002,100(4):665-670.
[1]Azziz R, Carmina E, Dewailly D,et al.Positions statement:criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome:an Androgen Excess Society guideline.J Clin Endocrinol Metab.2006;91(11): 4237-4245.
[2]King J.Polycystic ovary syndrome.J Midwifery Womens Health.2006; 51(6): 415-422.
[3]Tsilchorozidou T, Overton C, Conway GS.The pathophysiology of polycystic ovary syndrome.Clin Endocrinol (Oxf).2004;60(1):1-17.
[4]Ehrmann DA, Barnes RB, Rosenfield RL,et al Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome.Diabetes Care.1999;22(1):141-46.
[5]Balen AH, Tan SL, MacDougall J, et al. Miscarriage rates following in-vitro fertilization are increased in women with polycystic ovaries and reduced by pituitary desensitization with buserelin. Human Reproduction (Oxford, England) 1993,8:959-964.
[6]Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group.Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome.Fertil Steril.2004;81(1):19-25.
[7]多囊卵巢综合征诊断,中华人民共和国卫生行业标准.中华人民共和国卫生部于2011.7.1发布,2011.12.1实施。
[8]Stein I and Leventhal M.Amenorrhea associated with bilateral polycystic ovaries. Am J Obstet Gynecol.1935; 29,181-191.
[9]Berga S1, Yen SS. Opioidergic regulation of LH pulsality in women with polycystic ovary syndrome. Clin Endocrinol 1989;30:177-184.
[10]Lockwood GM, Muttukrishna S, Groome NP,et al.Mid-follicular phase pulses of inhibin B are absent in polycystic ovarian syndrome and are initiated by successful laparoscopic ovarian diathermy:a possible mechanism regulating emergence of the dominant follicle.J Clin Endocrinol Metab.1998;83(5):1730- 1735.
[11]Zhang L, Rodriguez H, Ohno S, Miller WL. Serine phosphorylation of human P450 C17 increases 17, zo-lyase activity:Implications for adrenarche and the PCOS. Proc Natl Acad Sci 1995;92:10619-10623.
[12]Mutharasan P, Galdones E, Penalver Bernabe B,et al.Evidence for chromosome 2p16.3 polycystic ovary syndrome susceptibility locus in affected women of European ancestryJ Clin Endocrinol Metab.2013;98(1):E185-190.
[13]Bahceci M, Tuzcu A, Bahceci S,et al.Is hyperprolactinemia associated with insulin resistance in non-obese patients with polycystic ovary syndrome?J Endocrinol Invest.2003;26(7):655-659.
[14]YenSS,VelaP, RankinJ.Inappropriate secretion of follicle stimulating Hormone in Polycystic ovarian disease J Clin Endocrionol Metab.1970:30:435-442
[15]Talbi S, Hamilton AE, Vo KC, et al. Molecular phenotyping of human endometrium distinguishes menstrual cycle phases and underlying biological processes in normo-ovulatory women. Endocrinology,2006; 147:1097-1121.
[16]Gurpide E, Gusberg SB & Tseng L. Estradiol binding and metabolism in human endometrial hyperplasia and adenocarcinoma. The Journal of Steroid Biochemistry,1976:7:891-896.
[17]Falany JL & Falany CN. Regulation of estrogen sulfotransferase in human endometrial adenocarcinoma cells by progesterone. Endocrinology,1996,137: 1395-1401.
[18]Venturoli S, Porcu E, Fabbri R et al. Episodic pulsatile secretion of FSH, LH, prolactin, oestradiol, oestrone, and LH circadian variations in polycystic ovary syndrome. Clinical Endocrinology 1988,28:93-107.
[19]Elliott JL, Hosford SL, Demopoulos RI et al. Endometrial adenocarcinoma and polycystic ovary syndrome:risk factors, management, and prognosis. Southern Medical Journal 2001; 94:529-531.
[20]Cheung AP. Ultrasound and menstrual history in predicting endometrial hyperplasia in polycystic ovary syndrome. Obstetrics and Gynecology 2001; 98: 325-331.
[21]Chekir C, Nakatsuka M, Kamada Y et al. Impaired uterine perfusion associated with metabolic disorders in women with poly cystic ovary syndrome [J]. Aeta Obstet Gyneeol Stand,2005,84(2):189-195.
[22]魏丽坤,张雷,王葛明,等.PCOS患者植入窗期子宫内膜胞饮突的变化表达.山东医药,2009,42(26)：5-6.
[23]Hess A, Nayak N & Giudice LC. Cyclic changes in primate oviduct and endometrium. In Knobil E &Neill JD (eds.) The physiology of reproduction. San Diego:Academic Press,2005.
[24]Mertens HJ, Heineman MJ, Theunissen PH et al. Androgen, estrogen and progesterone receptor expression in the human uterus during the menstrual cycle. European Journal of Obstetrics, Gynecology, and Reproductive Biology 2001; 98:58-65.
[25]Apparao KB, Lovely LP, Gui Yet al. Elevated endometrial androgen receptor expression in women with polycystic ovarian syndrome. Biology of Reproduction 2002; 66:297-304.
[26]Quesada S, Avellaira C, Johmn MC et al. Evaluation of steroid receptors, coregulators and molecules associated with uterine receptivity in secretory endometria from untreated women with polycystic ovary syndrome[J]. Fertil Sterit,2006,85(4):1017-1026.
[27]Lathi RB, Swiersz L, Basina M & Giudice LC. The endometrium in polycystic ovary syndrome. Current Opinion on Endocrinology Diabetes 2002; 9: 480-485.
[28]Giudice LC, Dsupin BA & Irwin JC. Steroid and peptide regulation of insulin-like growth factor-binding proteins secreted by human endometrial stromal cells is dependent on stromal differentiation. The Journal of Clinical Endocrinology and Metabolism 1992; 75:1235-1241.
[29]Lathi RB, Hess AP, Tulac S et al. Dose-dependent insulin regulation of insulin-like growth factor binding protein-1 in human endometrial stromal cells is mediated by distinct signaling pathways. The Journal of Clinical Endocrinology and Metabolism 2005; 90:1599-1606.
[30]Nayak N & Giudice LC. Comparative biology of the IGF system in endometrium, decidua, and placenta, and clinical implications for foetal growth and implantation disorders. Placenta 2003; 24:281-296.
[31]Zhou J, Dsupin BA, Giudice LC & Bondy CA. Insulin-like growth factor system gene expression in human endometrium during the menstrual cycle. The Journal of Clinical Endocrinology and Metabolism 1994; 79:1723-1734.
[32]Ballard FJ, Walton PE, Bastian S et al. Effects of interactions between IGFBPs and IGFs on the plasma clearance and in vivo biological activities of IGFs and IGF analogues. Growth Regulation 1993; 3:40-44.
[33]Palecek SP, Loftus JC, Ginsberg MH, et al. Integrin-ligand binding properties govern cell migration speed through cell-substratum adhesiveness. Nature, 1997,385:537-540.
[34]Palecek SP, Loftus JC, Ginsberg MH, et al. Integrin-ligand binding properties govern cell migration speed through cell-substratum adhesiveness. Nature, 1997,385:537-540.
[35]Sjaasta MD et al. BioEssays.1997,19:47-51.
[36]Shimizu Y et al. Immunol Today.1996,17:565-561.
[37]Lessey BA, Ilesanmi A O, Lessey M A, et al. Luminal and glandular endometrial epithelium express integrins differentially throughout the menstrual cycle:implications for implantation, contraception, and infertility. Am JReprod Immunol, 996,35(3):195-200.
[38]李蓉,乔杰,王威,等.多囊卵巢综合征患者着床窗口期子宫内膜容受性的改变.中国优生与遗传杂志,2007,10(5)：23-25.
[39]Quesada S, Avellaira C. Johmn MC, et al. Evaluation of steroid receptors, coregulators, and molecules associated with uterine receptivity in secretory endometria from untreated women with poly cystic ovary syndrome [J]. Fertil Steril,2006,85(4):1017-1026.
[40]刘丽丽,乔杰,王玉真.瘦素及其受体系统在子宫内膜的表达.锦州医学院学报,2003,24(3)：43-.45.
[41]王玉真,刘丽丽,乔杰.瘦素及瘦素长受体在多囊卵巢综合征患者子宫内膜的表达.中华妇产科杂志,2003,38(1)：72-101.
[42]Agarwal SK, Vogel K, Weitsman SR, et al. Leptin antagonizes the insulin-lile growth factor laugementation of stteroidogenesis in granulose and theca cells of the human ovary. Clin Endocrinol Metab,1998,84(30:1072-1076.
[43]王俊杰,雷小敏,易慕华.PCOS患者着床窗口期子宫内膜组织中MMP-2、 MMP-9、TIMP-1的表达变化及意义.山东医药,2009,50(49)：13-15.
[44]Emily B, Susan J, Patric RS et al. Proc Natl Acad Sci USA,1996, 93(7):3115-3120.
[45]罗桐秀,黄春霞.人类HOX基因改变导致肢体畸形的研究进展.国外医学遗传学分册,2005,28(2),105-108.
[46]Vitiello D, Pinard R, Taylor HS. Gene expression profiling reveals putative HOXA10 downstream targets in the periimplantation mouse uterus [J]. Reprod Sci,2008,15(5):529-535.
[47]Cermik D, Selam B,Taylor HS. Regulation of HOXA-10 expression by testosterone in vitro and in the endometrium of patients with polycystic ovary syndrome[J]. J Clin Endocfinol Metab,2003,88(1):238-243.
[48]何泓,钟刚,濮德敏等.性激素与HOXA10基因调控关系的研究进展[J].生殖与避孕,2010,30(3)：212-215.
[49]Glueck CJ,Wang P,GoldenbergN, et al. Pregnancy outcomes among women with polycystic ovary syndrome treated with metformin. Hum Reprod,2002,17 (11):2858-2864.
[50]Cermik D, Selam B, Taylor HS. Regulation of HOXA-10 expression by testosterone in vitro and in the endometrium of patients with polycystic ovary syndrome. J Clin Endocrinol Metab,2003,88(1):238-243.
[51]Boomsma CM, Eijkemans MJ, Hughes EG. A meta-analysis of pregnancy outcomes in women with polycystic ovary syndrome. Hum Reprod Update 2006;12:673-83.
[52]Kiddy DS, Hamilton-Fairley D, Bush A, Short F,et al. Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 1992;36:105-11.
[53]Imani B, Eijkemans MJ, te Velde ER, Habbema JD. A nomogram to predict the probability of live birth after clomiphene citrate induction of ovulation in normogonadotropic oligoamenorrheic infertility. Fertil Steril 2002;77:91-7.
[54]Eijkemans MJ, Imani B, Mulders AG, Habbema JD, Fauser BC. High singleton live birth rate following classical ovulation induction in normogonadotrophic anovulatory infertility (WHO). Hum Reprod 2003;18:2357-62.
[55]Amer SA, Laird s, Ledger WL, et al. Effect of laparoseopie ovarian diathermy on circulating inhibin B in women with anovulatorypolycystic ovary syndrome[J]. HumReprod,2007,22(2):389-394.
[56]高贵花,魏兆莲,曹云霞等.不同控制性促排卵方案对多囊卵巢综合症患者体外受精-胚胎移植治疗效果的影响[J].中国妇幼保健,2008,23(36)：5167-5169.DOI:10.3969/j.issn.1001-4411.2008.36.036.
[57]YenSSC· Polycystic ovary syndrome reproductive endocrinology 4th ed, Philadelphia, WBSaunders,1999-436-478.
[58][58]YenSS, VelaP, RankinJ.Inappropriate secretion of follicle stimulating Hormone in Polycystic ovarian disease J Clin Endocrionol Metab1970:30:435-442
[59]Robert J Norman, Ruijin Wu and Marcin T. Stankiewicz.Polycystic ovary syndrome.MJA,2004,180:132-137.
[60]Giudice LC. Elucidating endometrial function in the post-genomic era. Human Reproduction Update,2003,9:223-235.
[2]Franks S, Stark J, Hardy K. Follicle dynamics and anovulation in polycystic ovary syndrome[J]. Hum Reprod Update:2008,14(4):367-378.
[3]Achache H, Revel A. Endometrial receptivity markers,the journey to successful embryo implantation[J].Hum Reprod Update:2006,12(6):731-746.
[4]陈骞,孙海翔,胡娅莉,等.子宫内膜厚度对体外受精-胚胎移植治疗结局的影响[J].生殖与避孕,2008,28(12)：730-733.
[5]Jarvela IY, Sladkevidius P, Kelly S, et al. Evaluation of endometrial receptivity during in-vitro fertiliazation using three-dimensional power Doppler ultrasound. Ultrasound Obstet Gynencol[J].2005,26(7):765-769.
[6]邵明君,叶碧绿,赵军招,等.体外受精-胚胎移植在多囊卵巢综合征不育患者中的应用[J].生殖医学杂志,2005,14(1)：10-12.
[7]高洪伟,张琳.影响PCOS女性IVF-ET结局的内分泌代谢因素及其药物干预[J].药品评价,2012,25(4)：19-23.
[8]张云山,张凤英,高企贤.LH在卵泡发育及卵巢刺激中的作用[J].国外医学(计划生育分册),2002,21(3)：12-16.
[9]Kurzawa R, Ciepiela P, Baczkowski T, et al. Comparison of embryological and clinical outcome in GnRH antagonist vs. GnRH agonist protocols for in vitro fertilization in PCOS non-obese patients. A prospective randomized study [J]. J Assist Reprod Genet,2008,25(8):365-374.
[10]Porter RN, Smith W, Craft L, et al. Induction of ovulation for in vitro fertilization using buserelin and gonadotropins [J]. Lancet,1984,2(8414): 1284-1285.
[11]Lainas TG, Sfontouris IA, Zorzovilis IZ, et al. Fleible GnRH antagonist protocol versus GnRH agonist long protocol in patients with polycystic ovary syndrome treated for IVF:a prospective randomized controlled trial (RCT)[J] Hum Reprod,2010,25(3):683-689.
[12]Palep-Singh M, Picton HM, Vrotsou K, et al. South asian women with polycystic ovary syndrome exhibit greater sensitivity to gonadotropin stimulation with reduced fertilization and ongoing pregnancy rates than their Caucasian counterparts [J]. Eur J Obstet Gynecol Reprod Bio, 2007,134(2):202-207.
[13]Thessaloniki ESHRE/ASRM-Sponsored PCOS Consensus workshop group. Consensus on infertility treatment related to polycystic ovary syndrome[J]. Hum Reprod,2008,23(3):462-477.
[14]Surrey MD, Kaylen M, Silverberg MD, et al. Effect of prolonged gonadotropin-releasing hormone agonist therapy on the outcome of in vitro fertilization-embryo transfer in patients with endometriosis[J]. Fertil Steril, 2002,78(4):699-704.
[15]Rickes D, Nickel I, Kropf S. Increased pregnancy rates after ultralong postoperative therapy with gonadotropin releasing hormone analogs in patients with endometriosis[J]. Fertil Steril,2002,78(4):757-762.
[16]徐仙,宋梦玲.子宫内膜容受性的临床应用的研究进展[J].宁夏医学杂志,2011,33(9)：799-802.
[17]Nardo LG, Sabatini L, Rai R, et al. Pinopode Expression During Human Implantation [J]. Eur Obstet Gyncol Reprod Biol,2002,101(2):104-108.
[18]Liatsikos SA, Grimbizis GF, Georgiou I,et al. HOXA10 and HOXA11 mutation scan in congenital malformations of the female genital tract [J]. Reprod Biomed Online,2010,21(1):126-132.
[19]Ye X, Hama K, Contos JJ. LPA3-mediated lysophosphatidic acid signalling in embryo implantation and spacing [J]. Nature,2005,435:104-108.
[20]Kotaro H, Junken A, Koji B:Lysophosphatidic receptor, LPA3, is positively and negatively regulated by progesterone and estrogen in the mouse uterus [J]. Life Sciences,2006,79:1736-1740.
[21]Katarzyna K, Marta W, Iona B:Quantitative expression of lysophosphatidic acid receptor 3 gene in porcine endometrium during the periimplantation period and estrous cycle [J]. Prostaglandins other lipid mediators,2008,85:26-32.
[22]Hanna A, Avi T, Diana P:Defective endometrial prostaglandin synthesis identified in patients with repeated implantation failure undergoing in vitro fertilization [J]. Fertility and Sterility,2010,94:1271-1278
[23]Qingxiang W, Teresa F, Pamela S:Reduced expression of biomarkers associated with the implantation window in women with endometriosis [J]. Fertility and Sterility 2009,91:1686-1691
[24]Cha KY, Koo JJ, Choi DH, et al. Pregnancy after in vitro fertilization of human follicular oocytes collected from non-stimulated cycles, their culture in vitro and their transfer in a donor oocyte program [J]. Fertil Steril,1991,55(2):109-113.
[25]Jaroudi KA, Hollanders JMG, Elnour AM, et al. Embryo development and pregnancies from in vitro matured and fertilized human oocytes [J]. Human Reproduction,1999,14(9):1749-1751
[26]Cobo AC, Requena A, Neuspiller F, et al. Navarro J. Maturation in vitroof human oocytes from unstimulated cycles:selection of the optimal day for ovum retrieval based on follicular size [J]. Human Reproduction,1999,14:1864-1868.
[27]Chian RC, Buckett WM, Tulandi T, et al. Prospective randomized study of human chorionic gonadotrophin priming before immature oocyte retrieval from unstimulated women with polycystic ovarian syndrome[J]. Human Reproduction,2000,15:150-170.
[28]Wynn P, Picton HM, Krapez JA, et al. Pretreatment with follicle stimulating hormone promotes the numbers of human oocytes reaching metaphase II by in vitro maturation[J]. Human Reproduction,1998,13:3132-3138.
[29]Li Yuan, Cheng ZiJiang, Zhao LiXin, et al. A case of clinic pregnacy after oocyte in vitro maturation and IVF-ET [J]. National Journal of Andrology, 2002,8:70-71.
[30]Heijnen EM, Eijkemans MJ, Hughes EG, et al. A meta-analysis of outcomes of conventional IVF in women with polycystic ovary syndrome [J]. Human Reproduction Update,2006,12(1):13-21.
[31]Balasch J, Fernandomez G, Casamitjana R, et al. Pituitary-ovarian suppression by the standard and half-doses of D-Trp-6-luteinizing hormone-releasing hormone depot [J]. Hum Reprod,1992,7(9):1230-1234
[32]李晓红,武学清,王嵩,等.减量促性腺激素释放激素激动剂在促排卵中的应用[J]. 生殖医学杂志,2003,12(3)：146-149.
[33]Ziecik AJ, Derecka-Reszka K and Rzucidlo SJ. Extragonadal gonadotropin receptors their distribution and function [J]. J Physiol Pharmacol,1992,4:33-49
[34]Pellatt L,Hanna L,Brincat M,et al. Granulosa cell production of anti-Mullerian hormone is increased in Polycystic Ovaries [J]. Journal of Clinical Endocrinology an Metabolism,2007,92:240-245
[35]邹燕琴,李红.多囊卵巢综合症患者自然流产的相关因素分析[J].国外医学计划生育分册.2004,23(4)：219-221
[36]Eman A. Elgindy, M.D. Progesterone level and progesterone/estradiol ratio on the day of hCG administration:detrimental cutoff levels and new treatment strategy[J]. Fertility and Sterility,2011,95(5):1639-1644.
[37]Ze Wu, Rong Li, Yanping Ma,Effect of HCG-day serum progesterone and oestradiol concentrations on pregnancy outcomes in GnRH agonist cycles [J]. Reproductive BioMedicine Online,2012,24 (5):511-520.
[38]Li R, Qiao J, Wang L, Zhen X, Lu Y. Serum progesterone concentration on day of HCG administration and IVF outcome [J]. Reprod Biomed Online. 2008;16(5):627-31
[39]Rickes D, Nickel I, Kropf S. Increased pregnancy rates after ultralong postoperative therapy with gonadotropin releasing hormone analogs in patients with endometriosis [J]. Fertil Steril,2002,78(4):757-762.
[40]Young KA, Chaffin CL, Molskness TA, et al., Controlled ovulation of the dominant follicle:a critical role for LH in the late follicular phase of the menstrual cycle [J].Hum. Reprod.2003,18:2257-2263.
[41]C.A.Venetis1, E.M.Kolibianakisl,3, E.Papanikolaou, et al., Is progesterone elevation on the day of human chorionic gonadotrophin administration associated with the probability of pregnancy in in vitro fertilization? A systematic review and meta-analysis [J]. Human Reproduction Update,2007, 13(4):343-355.
[42]Bosch E, Valencia I, Escudero E, Premature luteinization during gonadotropin-releasing hormone antagonist cycles and its relationship with in vitro fertilization outcome, [J] Fertility and Sterility,2003,80:1444-1449.
[43]Eman A. Elgindy, M.D. Progesterone level and progesterone/estradiol ratio on the day of hCG administration:detrimental cutoff levels and new treatment strategy [J]. Fertility and Sterility,2011,95(5):1639-1644.
[44]Ze Wu, Rong Li, Yanping Ma, Effect of HCG-day serum progesterone and oestradiol concentrations on pregnancy outcomes in GnRH agonist cycles [J].Reproductive BioMedicine Online,2012,24 (5):511-520.
[45]raoul Orvieto, Simion Meltcer, Gad Liberty, et al., Does day-3 LH/FSH ratio influence in vitro fertilization outcome PCOS patients undergoing controlled ovarian hyperstimulatio with different GnRH-analogue[J]? Gynecological Endocrinology,2012,28(6):422-424.
[46]Sharara FI.Lim J.McClamrock HD Endometrial pattern on the day of oocyte retrieval is more predictive of implantation success than the pattern or thickness on the day of hCG administration[J]. J Assist Reprod Genat.1999,16(101): 523-528.
[47]Xingqi Zhang, Chi-Huang Chen, Edmond Confino,et al.,Increased endometrial thickness is associated with improved treatment outcome for selected patients undergoing in vitro fertilization-embryo transfer [J].Fertility and Sterility,2005, 83(2):336-340.
[48]I. Y. J ARVELA, P. SLADKEVICIUS, S. KELLY, et al., Evaluation of endometrial receptivity during in-vitro fertilization using three-dimensional power Doppler ultrasound.[J].Ultrasound Obstet Gynecol,2005,26:765-769.
[49]Gonen Y, Casper RF. Prediction of implantation by the sonographic appearance of the endometrium during controlled ovarian stimulation for in vitro fertihzation [J]. J In Vitro Fert Embryo Trand,1990,7(3):146-152.
[50]A.M.E. Lintsen, P.C.M. Pasker-de Jong, E.J. de Boer, et al.Effects of subfertility cause, smoking and body weight on the success rate of IVF[J]. Human Reproduction 2005,20 (7):1867-1875
[51]Chien LW, Au HK, Chen PL, Xiao J, Tseng CR. Assessment of uterine receptivity by the endometrial-subendometrial blood flow distribution pattern in women undergoing in vitro fertilization-embryo transfer [J]. Fertility and Sterility 2002;78:245-51.
[52]Ernest Hung Yu Ng*, Carina Chi Wai Chan, Oi Shan Tang, et al., The role of endometrial blood flow measured by three-dimensional power Doppler ultrasound in the prediction of pregnancy during in vitro fertilization treatment [J].European Journal of Obstetrics & Gynecology and Reproductive Biology, 2007,135:8-16.
[53]Raine-Fenning NJ, Campbell BK, Kendall NR, Clewes JS, John-son IR. Quantifying the changes in endometrial vascularity throughout the normal menstrual cycle with three-dimensional power Doppler angiography [J]. Hum Reprod 2004; 19:330-338.
[54]Okuhue JE, Onuh SO, Ebeigbe P, Shaibu I, Wada I, et al., The effect of endometrial thickness on in vitro fertilization (IVF)-embryo transfer/ intracytoplasmic sperm injection (ICSI) outcome[J].Afr J Reprod Health,2009 13:113-121.
[55]Traub ML, Van Arsdale A, Pal L, Jindal S, Santoro N, Endometrial thickness, Caucasian ethnicity, and age predict clinical pregnancy following fresh blastocyst embryo transfer:a retrospective cohort [J].Reprod Biol Endocrinol 2009,7:33.
[56]Rashidi BH, Sadeghi M, Jafarabadi M, Tehrani Nejad ES, Relationships between pregnancy rates following in vitro fertilization or intracytoplasmic sperm injection and endometrial thickness and pattern[J].Eur J Obstet Gynaecol Reprod Biol,2005,120:179-184.
[57]Kinay T, Tasci Y, Dilbaz S, Cinar O, Demir B et al., The relationship between endometrial thickness and pregnancy rates in GnRH antagonist down-regulated ICSI cycles[J].Gynecol Endocrinol,2010,26:833-837.
[58]Emma Boys and Michael Chapman, The Influence of Endometrial Thickness on IVF Outcomes[J]. J Fert In Vitro,2012,2 (2):2-4.
[59]A.M.E. Lintsen, P.C.M. Pasker-de Jong, E.J. de Boer, et al.Effects of subfertility cause, smoking and body weight on the success rate of IVF [J]. Human Reproduction 2005,20 (7):1867-1875
[60]Emily S. Jungheim, Susan E. Lanzendorf, et al., Morbid obesity is associated with lower clinical pregnancy rates after in vitro fertilization in women with polycystic ovary syndrome[J]. Fertility and Sterility,2009,92(1):256-261.
[61]Megan L. Sneed, Meike L. Uhle, H. Edward Grotjan,et al., Body mass index: impact on IVF success appears age-related. [J] Human Reproduction,2008, 23(8):1835-1839.
[62]M Metwally, R Cutting, A Tipton, et al., Effect of increased body mass index on oocyte and embryo quality in IVF patients, Reproductive BioMedicine Online. [J].2007,15(5):532-538.
[63]Stavreus. Evers A, Nikas G, Sahlin L, et al. Formation of pinopodes in humau endometrium is associated with the concentrations of progesterone and progesterone receptors[J]. Ferlil Steril,2001,76(41):782-791.
[64]Hambartsoumian E. Endometrial leukemia inhibitory factor (LIF)as a possible cause of unexplained infertility and multiple failures of implantation[J]. Am J Reprod lmmunol,1998,39(2):137-142
[65]Psychoyos A, Mandon P. Scanning electron microscopy of the surface of the rat uterine epithelium during delayed implantation[J]. J Reprod Fertil,1971,26(1): 137-139
[66]Nikas G, Develioglu O H, Toner J P, et al. Endometrial Pinopodes Indicate A Shift in the Window Receptivity in IVF Cycles [J]. Hum Reprod,1994,14(3):787-792.
[67]Sunder S, Lenton EA. Endocrinology of the peri-implantation period[J]. Baillieres Best Pract Res Clin Obstet Gynaecol,2000,14(5):789-791
[68]Martel D, Monier M N, Roche D, et al. Hormonal Dependence of Pinopode Formation at the Uterine Luminal Surface [J]. Hum Reprod, 1991,6(4):597-603.
[69]Murthi P, Hiden U, Rajaraman G, et al. Novel homeobox genes are differentially expressed in placental microvascular endothelial cells compared with microvascular cells[J]. Placenta,2008,29(2):624-630.
[70]Wei Q, St Clair JB, Fu T, et al. Reduced expression of biomarkers associated with the implantation window in women with endometriosis [J]. Fertil Steril, 2009,91(3):1686-1691.
[71]Block K, Kardana A, Igarashi P, et al. In utero diethylstilbestrol(DES) exposure alters Hox gene expression in the developing mullerian system [J]. FASEB J,2000,14(3):1101-1108
[72]Salih SM, Taylor HS. HOXA10 gene expression in human fallopian tube and ectopic pregnancy [J]. Am J Obstet Gynecol,2004,190(7):1404-1406.
[73]Lee B, Du H, Tayler HS, Experimental murine endometriosis induces DNA methylation and altered gene expression in eutopic endometrium [J]. Biol Reprod,2009,80(7):79-85.
[74]Ye X. Jerold Chun. Lysophosphatidic Acid (LPA) signaling in vertebrate reproduction. Trends Endocrinol Metab.2010.21(1):17-26
[75]Guo Hui, Gong Fei, Luo Keli, LU guangxiu. Cyclic regulation of LPA3 in human endometrium [J]. Archives of Gynecology and Obstetrics,2012,7(18):321-324.
[76]Trounson A, Wood C, Kausche A.In vitro maturation and the fertilization and developmental competence of oocytes recoverd from untreated polycystic ovarian patients[J].Fertil Steril,1994,62 (2):353-362.
[77]Le Du A, Kadoch I.J, Bourcigaux N, et al.In vitro oocyte maturation for the treatment of infertility associated with polycystic ovarian syndrome.the French experience[J]. Hum Reprod,2005,20(2):420-424.
[78]Mikkelsen AL. Srtategies in human in-vitro maturation and their clnical outcome[J]. Reprod BioMed Online,2005,10(5):593-599.
[79]Chian RC, Bucket WM, Tulandi T, et al. Prospective randomized study of human chorionic gonadotrophin riming before immature oocyte retrieval from unstimulated women with polycystic ovarian syndrome[J]. Hum Reprod,2000, 15(1):165-170.
[80]Hreinsson J, Rosenlund B, Friden B, et al. Recombination LH is equally effective as recombinate HCG in promoting oocyte maturation in a clinical in-vitro maturation programme:a randomized study[J]. Hum Reprod,2003, 18(10):2131-2136.
[81]Child TJ, Abdul-Jalil AK, Gulekli B, et al. In vitro maturation and fertilization of oocytes from unstimulate dnormal ovaries, polycystic ovaries, and women with polycystic ovarysyndrome[J]. Fertil Steril,2001,76(5):936-942.
[82]Wynn P, Picton HM, Krapez JA, et al. Pretreatment with follicle stimulating hormone promotes the numbers of human oocytes reaching metaphase II by in-vitro maturation [J]. Hum Reprod,1998,13 (11):3132-3138.
[83]Cortvrindt R, Smitz J, Steirteghem ACV. In-vitro maturation, fertilization and embryo development of immature oocytes from early preantral follicles from prepuberal mice in a simplified culture system[J]. Hum Reprod, 1996,11(12):2656-2666.
[84]Child TJ, Sylvestre C, Pirwanyl, et al. Basal serum levels of FSH and estradiol in ovulatory and anovulatory women undergoing treatment by in-vitro maturation of immature oocytes[J]. Hum Reprod,2002,17 (8):1997-2002.
[85]Kim BK, Lee SC, Kim KJ, et al. In vitro maturation, fertilization, and development of human germinal vesicle oocytes collected from stimulated cycles[J]. Fertil Steril,2000,74(6):1153-1158.
[86]Mikkelsen AS, Smith SD & Lindenberg S. In-vitro maturation of human oocytes from regular menstruating women may be successful without follicoe stimulationg hormone priming[J]. Hum Reprod,1999,14(7):1847-1851.
[87]Noyes N, Liu HC, Sultan, K, et al. Endometrial thickness appears to be a significant factor in embryo implantation in in-vitro fertilization [J]. Hum Reprod,1995,10(4):919-922.
[88]Rinaldi L, Lisi F, Floccari A, et al. Endometrial thickness as a predictor of pregnancy after in-vitro fertilization but not after intra cytoplasmic sperm injection[J]. Hum Reprod,1996,11(7):1538-1541.
[89]Suikkari A-M, Tulppala M, Tuuri T, et al. Luteal phase start of low-dose FSH priming of follicles results in an effient recovery, maturation and fertilization of immature human oocytes[J]. Hum Reprod,2000,15(4):747-751.
[90]Schield RL, Knobloch C, Dorn C, et al. Endometrial receptivity in an in vitro fertilization program as assessed by spiral artery blood flow, endometrial thickness, endometrial volume,and uterine artery blood flow[J]. Fertil Steril, 2001,75(2):361-366.
[91]Child TJ, Phillips SJ, Abdul-Jalil AK, et al. A comparison of in vitro maturation and in vitro fertilization for women with polycystic ovaries[J]. Obstet Gynecol, 2002,100(4):665-670.
[1]Azziz R, Carmina E, Dewailly D,et al.Positions statement:criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome:an Androgen Excess Society guideline.J Clin Endocrinol Metab.2006;91(11): 4237-4245.
[2]King J.Polycystic ovary syndrome.J Midwifery Womens Health.2006; 51(6): 415-422.
[3]Tsilchorozidou T, Overton C, Conway GS.The pathophysiology of polycystic ovary syndrome.Clin Endocrinol (Oxf).2004;60(1):1-17.
[4]Ehrmann DA, Barnes RB, Rosenfield RL,et al Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome.Diabetes Care.1999;22(1):141-46.
[5]Balen AH, Tan SL, MacDougall J, et al. Miscarriage rates following in-vitro fertilization are increased in women with polycystic ovaries and reduced by pituitary desensitization with buserelin. Human Reproduction (Oxford, England) 1993,8:959-964.
[6]Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group.Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome.Fertil Steril.2004;81(1):19-25.
[7]多囊卵巢综合征诊断,中华人民共和国卫生行业标准.中华人民共和国卫生部于2011.7.1发布,2011.12.1实施。
[8]Stein I and Leventhal M.Amenorrhea associated with bilateral polycystic ovaries. Am J Obstet Gynecol.1935; 29,181-191.
[9]Berga S1, Yen SS. Opioidergic regulation of LH pulsality in women with polycystic ovary syndrome. Clin Endocrinol 1989;30:177-184.
[10]Lockwood GM, Muttukrishna S, Groome NP,et al.Mid-follicular phase pulses of inhibin B are absent in polycystic ovarian syndrome and are initiated by successful laparoscopic ovarian diathermy:a possible mechanism regulating emergence of the dominant follicle.J Clin Endocrinol Metab.1998;83(5):1730- 1735.
[11]Zhang L, Rodriguez H, Ohno S, Miller WL. Serine phosphorylation of human P450 C17 increases 17, zo-lyase activity:Implications for adrenarche and the PCOS. Proc Natl Acad Sci 1995;92:10619-10623.
[12]Mutharasan P, Galdones E, Penalver Bernabe B,et al.Evidence for chromosome 2p16.3 polycystic ovary syndrome susceptibility locus in affected women of European ancestryJ Clin Endocrinol Metab.2013;98(1):E185-190.
[13]Bahceci M, Tuzcu A, Bahceci S,et al.Is hyperprolactinemia associated with insulin resistance in non-obese patients with polycystic ovary syndrome?J Endocrinol Invest.2003;26(7):655-659.
[14]YenSS,VelaP, RankinJ.Inappropriate secretion of follicle stimulating Hormone in Polycystic ovarian disease J Clin Endocrionol Metab.1970:30:435-442
[15]Talbi S, Hamilton AE, Vo KC, et al. Molecular phenotyping of human endometrium distinguishes menstrual cycle phases and underlying biological processes in normo-ovulatory women. Endocrinology,2006; 147:1097-1121.
[16]Gurpide E, Gusberg SB & Tseng L. Estradiol binding and metabolism in human endometrial hyperplasia and adenocarcinoma. The Journal of Steroid Biochemistry,1976:7:891-896.
[17]Falany JL & Falany CN. Regulation of estrogen sulfotransferase in human endometrial adenocarcinoma cells by progesterone. Endocrinology,1996,137: 1395-1401.
[18]Venturoli S, Porcu E, Fabbri R et al. Episodic pulsatile secretion of FSH, LH, prolactin, oestradiol, oestrone, and LH circadian variations in polycystic ovary syndrome. Clinical Endocrinology 1988,28:93-107.
[19]Elliott JL, Hosford SL, Demopoulos RI et al. Endometrial adenocarcinoma and polycystic ovary syndrome:risk factors, management, and prognosis. Southern Medical Journal 2001; 94:529-531.
[20]Cheung AP. Ultrasound and menstrual history in predicting endometrial hyperplasia in polycystic ovary syndrome. Obstetrics and Gynecology 2001; 98: 325-331.
[21]Chekir C, Nakatsuka M, Kamada Y et al. Impaired uterine perfusion associated with metabolic disorders in women with poly cystic ovary syndrome [J]. Aeta Obstet Gyneeol Stand,2005,84(2):189-195.
[22]魏丽坤,张雷,王葛明,等.PCOS患者植入窗期子宫内膜胞饮突的变化表达.山东医药,2009,42(26)：5-6.
[23]Hess A, Nayak N & Giudice LC. Cyclic changes in primate oviduct and endometrium. In Knobil E &Neill JD (eds.) The physiology of reproduction. San Diego:Academic Press,2005.
[24]Mertens HJ, Heineman MJ, Theunissen PH et al. Androgen, estrogen and progesterone receptor expression in the human uterus during the menstrual cycle. European Journal of Obstetrics, Gynecology, and Reproductive Biology 2001; 98:58-65.
[25]Apparao KB, Lovely LP, Gui Yet al. Elevated endometrial androgen receptor expression in women with polycystic ovarian syndrome. Biology of Reproduction 2002; 66:297-304.
[26]Quesada S, Avellaira C, Johmn MC et al. Evaluation of steroid receptors, coregulators and molecules associated with uterine receptivity in secretory endometria from untreated women with polycystic ovary syndrome[J]. Fertil Sterit,2006,85(4):1017-1026.
[27]Lathi RB, Swiersz L, Basina M & Giudice LC. The endometrium in polycystic ovary syndrome. Current Opinion on Endocrinology Diabetes 2002; 9: 480-485.
[28]Giudice LC, Dsupin BA & Irwin JC. Steroid and peptide regulation of insulin-like growth factor-binding proteins secreted by human endometrial stromal cells is dependent on stromal differentiation. The Journal of Clinical Endocrinology and Metabolism 1992; 75:1235-1241.
[29]Lathi RB, Hess AP, Tulac S et al. Dose-dependent insulin regulation of insulin-like growth factor binding protein-1 in human endometrial stromal cells is mediated by distinct signaling pathways. The Journal of Clinical Endocrinology and Metabolism 2005; 90:1599-1606.
[30]Nayak N & Giudice LC. Comparative biology of the IGF system in endometrium, decidua, and placenta, and clinical implications for foetal growth and implantation disorders. Placenta 2003; 24:281-296.
[31]Zhou J, Dsupin BA, Giudice LC & Bondy CA. Insulin-like growth factor system gene expression in human endometrium during the menstrual cycle. The Journal of Clinical Endocrinology and Metabolism 1994; 79:1723-1734.
[32]Ballard FJ, Walton PE, Bastian S et al. Effects of interactions between IGFBPs and IGFs on the plasma clearance and in vivo biological activities of IGFs and IGF analogues. Growth Regulation 1993; 3:40-44.
[33]Palecek SP, Loftus JC, Ginsberg MH, et al. Integrin-ligand binding properties govern cell migration speed through cell-substratum adhesiveness. Nature, 1997,385:537-540.
[34]Palecek SP, Loftus JC, Ginsberg MH, et al. Integrin-ligand binding properties govern cell migration speed through cell-substratum adhesiveness. Nature, 1997,385:537-540.
[35]Sjaasta MD et al. BioEssays.1997,19:47-51.
[36]Shimizu Y et al. Immunol Today.1996,17:565-561.
[37]Lessey BA, Ilesanmi A O, Lessey M A, et al. Luminal and glandular endometrial epithelium express integrins differentially throughout the menstrual cycle:implications for implantation, contraception, and infertility. Am JReprod Immunol, 996,35(3):195-200.
[38]李蓉,乔杰,王威,等.多囊卵巢综合征患者着床窗口期子宫内膜容受性的改变.中国优生与遗传杂志,2007,10(5)：23-25.
[39]Quesada S, Avellaira C. Johmn MC, et al. Evaluation of steroid receptors, coregulators, and molecules associated with uterine receptivity in secretory endometria from untreated women with poly cystic ovary syndrome [J]. Fertil Steril,2006,85(4):1017-1026.
[40]刘丽丽,乔杰,王玉真.瘦素及其受体系统在子宫内膜的表达.锦州医学院学报,2003,24(3)：43-.45.
[41]王玉真,刘丽丽,乔杰.瘦素及瘦素长受体在多囊卵巢综合征患者子宫内膜的表达.中华妇产科杂志,2003,38(1)：72-101.
[42]Agarwal SK, Vogel K, Weitsman SR, et al. Leptin antagonizes the insulin-lile growth factor laugementation of stteroidogenesis in granulose and theca cells of the human ovary. Clin Endocrinol Metab,1998,84(30:1072-1076.
[43]王俊杰,雷小敏,易慕华.PCOS患者着床窗口期子宫内膜组织中MMP-2、 MMP-9、TIMP-1的表达变化及意义.山东医药,2009,50(49)：13-15.
[44]Emily B, Susan J, Patric RS et al. Proc Natl Acad Sci USA,1996, 93(7):3115-3120.
[45]罗桐秀,黄春霞.人类HOX基因改变导致肢体畸形的研究进展.国外医学遗传学分册,2005,28(2),105-108.
[46]Vitiello D, Pinard R, Taylor HS. Gene expression profiling reveals putative HOXA10 downstream targets in the periimplantation mouse uterus [J]. Reprod Sci,2008,15(5):529-535.
[47]Cermik D, Selam B,Taylor HS. Regulation of HOXA-10 expression by testosterone in vitro and in the endometrium of patients with polycystic ovary syndrome[J]. J Clin Endocfinol Metab,2003,88(1):238-243.
[48]何泓,钟刚,濮德敏等.性激素与HOXA10基因调控关系的研究进展[J].生殖与避孕,2010,30(3)：212-215.
[49]Glueck CJ,Wang P,GoldenbergN, et al. Pregnancy outcomes among women with polycystic ovary syndrome treated with metformin. Hum Reprod,2002,17 (11):2858-2864.
[50]Cermik D, Selam B, Taylor HS. Regulation of HOXA-10 expression by testosterone in vitro and in the endometrium of patients with polycystic ovary syndrome. J Clin Endocrinol Metab,2003,88(1):238-243.
[51]Boomsma CM, Eijkemans MJ, Hughes EG. A meta-analysis of pregnancy outcomes in women with polycystic ovary syndrome. Hum Reprod Update 2006;12:673-83.
[52]Kiddy DS, Hamilton-Fairley D, Bush A, Short F,et al. Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 1992;36:105-11.
[53]Imani B, Eijkemans MJ, te Velde ER, Habbema JD. A nomogram to predict the probability of live birth after clomiphene citrate induction of ovulation in normogonadotropic oligoamenorrheic infertility. Fertil Steril 2002;77:91-7.
[54]Eijkemans MJ, Imani B, Mulders AG, Habbema JD, Fauser BC. High singleton live birth rate following classical ovulation induction in normogonadotrophic anovulatory infertility (WHO). Hum Reprod 2003;18:2357-62.
[55]Amer SA, Laird s, Ledger WL, et al. Effect of laparoseopie ovarian diathermy on circulating inhibin B in women with anovulatorypolycystic ovary syndrome[J]. HumReprod,2007,22(2):389-394.
[56]高贵花,魏兆莲,曹云霞等.不同控制性促排卵方案对多囊卵巢综合症患者体外受精-胚胎移植治疗效果的影响[J].中国妇幼保健,2008,23(36)：5167-5169.DOI:10.3969/j.issn.1001-4411.2008.36.036.
[57]YenSSC· Polycystic ovary syndrome reproductive endocrinology 4th ed, Philadelphia, WBSaunders,1999-436-478.
[58][58]YenSS, VelaP, RankinJ.Inappropriate secretion of follicle stimulating Hormone in Polycystic ovarian disease J Clin Endocrionol Metab1970:30:435-442
[59]Robert J Norman, Ruijin Wu and Marcin T. Stankiewicz.Polycystic ovary syndrome.MJA,2004,180:132-137.
[60]Giudice LC. Elucidating endometrial function in the post-genomic era. Human Reproduction Update,2003,9:223-235.